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ABSTRACT OF THE DISSERTATION
The Role of Autophagy and IL-17 in Bone Resorption
by
Carl J. DeSelm
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2012
Professor Steven Teitelbaum, Chairperson

Osteoclasts are essential for skeletal homeostasis (Teitelbaum, 2000). These
macrophage-lineage cells function by generating a polarized microenvironment between
themselves and bone wherein skeletal matrix is degraded. This resorptive compartment
is isolated from the general extracellular space by an actin ring which encompasses the
ruffled border, a convoluted plasma membrane structure formed by its fusion with
lysosome-related vesicles containing an electrogenic H+ATPase, a chloride channel,
LAMP-1, and cathepsin K. In consequence, resorption of bone reflects secretion of HCl
to mobilize mineral, and cathepsin K to degrade the collagen-rich organic matrix, into the
resorptive space (Stenbeck, 2002; Zhao et al., 2008). We determined that the two
ubiquitin-like conjugation systems required for macroautophagy are necessary for
generation of the osteoclast ruffled border. These autophagy proteins regulate the cell’s
capacity to efficiently secrete lysosomal proteins into the resorptive microenvironment
both in vitro and in vivo and thus its ability to degrade bone. These findings provide a
novel role for autophagy proteins and a possible mechanism to explain human genome

ii

wide association data suggesting a link between the autophagy pathway and
predisposition to osteoporosis (Zhang et al.).
Further studies in this thesis implicate IL-17 signaling in osteoporosis. Although
not traditionally thought of as an inflammatory disease, estrogen deficiency osteoporosis
is partially mediated by T cells, at least in mice (Weitzmann and Pacifici, 2007). Th17
cells, which secrete IL-17, mediate a number of inflammatory and autoimmune
conditions, including arthritis-mediated bone destruction. We find IL-17 critical in the
pathogenesis of bone loss due to estrogen deficiency. IL-17 receptor deficient mice are
protected from bone loss after ovariectomy, as are mice treated with a neutralizing IL-17
antibody. Mice treated with a small molecule inhibitor of IL-17 production are similarly
protected. The effect of IL-17 on osteoclasts is indirect, via osteoblastic upregulation of
RANKL. The SEFIR domain of IL-17R is critical for osteoblast-mediated osteoclast
formation and RANKL production. The adaptor protein Act1, specifically its SEFIR
domain, is required for osteoblast-mediated osteoclast formation in response to IL-17,
and Act1-/- mice are also protected from bone loss induced by estrogen deficiency.
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Preface
This thesis addresses several aspects of bone biology, focusing on novel
mechanisms in both the bone resorbing osteoclasts and bone forming osteoblasts. The
projects described in this manuscript progressed enough to reach public presentation
and/or publication, but they are the minority. My favorite in the pool of unsuccessful
projects was an attempt to derive human osteoblasts and osteoclasts from skin fibroblasts,
which would allow one to grow and study an individual’s bone-forming and boneresorbing cells to characterize their skeletal disease using only a skin biopsy. It would
also provide the opportunity to expand and/or modify the cells and re-introduce them, if
the methods became safe, into the same person to provide new or more functional bone
forming or resorbing cells without worry of rejection. The plan was ambitious, since
osteoclasts had never been differentiated from human stem cells, and since methods for
inducing pluripotency in fibroblasts had just been discovered. Nonetheless, we were able
to create pluripotent stem cells from fibroblasts, and were able to differentiate mouse
stem cells to osteoblasts and osteoclasts, but never succeeded in pushing human induced
stem cells into osteoblast or osteoclast lineages.
In the middle of this stem cell project, near the time of my qualifying exam, I
attended a talk on a new and interesting topic of autophagy, which I learned from
Pubmed was completely unstudied in the bone. The Virgin Lab was kind to share some
mouse bones from their autophagy deficient animals, so I started a side project to test
whether these autophagy proteins had a role in osteoclasts. It eventually became apparent
the cells had a defect in secretion, which was a hypothesized but unestablished role for
autophagy, thus spiking interest in the Virgin Lab and providing rationale for my mentor
v

to support pursuit of the project. I am very fortunate for the patience and freedom
allowed by my mentor, Steve Teitelbaum, who with great foresight gave me the
promising project of studying the role of IL-17 on bone disease in the very beginning,
and likely had points of annoyance along the way as I sacrificed time on this project to
pursue others as they jumped to mind. I am also lucky that even when I worked on IL17, Steve allowed me to pursue higher risk experiments that were not part of the defined
path, which often did not work. In the end I matured greatly, and learned how to better
recognize good and bad projects and identify the types of experiments that will quickly
disprove an idea or maximize its human relevance.
Since all projects in this thesis relate to the skeleton and to the osteoclast, the
general introduction provides background to importance of this cell and how it functions.
Within each chapter is more specific background to each project.
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Chapter 1: Introduction
Bone
Bones survive hundreds of years outside the body, but inside roughly 10% of each
bone is broken down per year in the adult, and 30-100% per year in the child (Nanci,
2008). Bone is composed of an organic component, which is 90% type I collagen and
10% other proteins such as osteocalcin and osteopontin, and an inorganic phase, which is
mainly calcium phosphate in the form of calcium hydroxyapetite. The osteoclast, the
lone bone-resorbing cell, secretes acid to dissolve the inorganic calcium phosphate
component, and proteases to break down the organic matrix. Each phase of bone
degradation is usually followed by a phase of bone formation by the osteoblast, resulting
in healthy bone remodeling and only gradual changes in bone mass. In pathological
states, such as osteoporosis, osteoclast activity is increased relative to that of the
osteoblast, causing net bone loss. Thus, most drug treatments for osteoporosis target the
osteoclast. On the contrary, when osteoclast activity is genetically impaired, bone
density is increased leading to osteopetrosis.

Osteoclast Development and Signaling
Osteoclasts are large, multinucleated cells that form by multiple fusions of
monocyte/macrophage precursors (Figure 1.1). Osteoclast differentiation and activation is
driven by macrophage-colony stimulating factor (M-CSF), and receptor activator of
nuclear factor-kappaB ligand (RANKL). RANKL is primarily produced by the
osteoblast, and is required for osteoclastogenesis (Theill, Boyle, & Penninger, 2002).

1

2 microns

Figure 1.1: The bone resorbing osteoclast
Electron micrograph of an osteclast in vivo. Osteoclasts are multinucleated cells that
secrete hydrogen ions and lysosomal enzymes over the bone surface. Convoluted, fingerlike projections of plasma membrane form at areas of active secretion.
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RANKL mainly exerts its differentiating effect by activating nuclear factor kappa B
(NFκB) signaling downstream of its receptor, RANK. A TNF-receptor family member,
RANK lacks intrinsic enzymatic activity, but recruits TRAF6, which then leads to not
only NFκB activation, but also that of mitogen-activated kinases (MAPKs), including Jun
N-terminal kinase (JNK) and p38 (Kobayashi et al., 2001; Lomaga et al., 1999; Naito et
al., 1999; Wong et al., 1998).
TRAF proteins are important in nearly all NFκB signaling pathways (Hacker &
Karin, 2006; Scheidereit, 2006). Of the seven TRAF proteins, TRAFs 2-7 have an Nterminal RING domain common to many E3 ubiquitin ligases. Ubiquitin ligase activity
has been most clearly established for TRAF 2 and 6. Unlike most ubiquitin ligases,
which target proteins for degradation, TRAF6-mediated ubiquitination primarily activates
downstream kinase cascades via K63 polyubiquitination (Deng et al., 2000; Wang et al.,
2001). TRAF6 E3 ligase activity is important in the activation of the IKK complex
leading to both canonical and noncanonical NF-κB pathways (Chen et al., 2006), and a
point mutation in a conserved region of the RING domain abolishes ubiquitination and
NFkB signaling (Deng et al., 2000). Auto-ubiquitination of TRAF6 via a Lys63-linked
polyubiquitin chain also mediates the recruitment of other mediators, resulting in
phosphorylation of IKK (Kanayama et al., 2004). Although TRAF6 knockout (KO) mice
exhibit severe osteopetrosis, it is unclear whether the defect is primarily due to
osteoclastogenesis or function. TRAF6 KO mice created by Naito et al showed
significantly fewer osteoclasts and impaired differentiation in vitro, while the knockout
mice created by Lomaga et al showed normal numbers of osteoclasts in vivo but impaired
ability of the cells to resorb bone (Kobayashi et al., 2001; Lomaga et al., 1999; Naito et
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al., 1999). In both cases, the mice were osteopetrotic.
NF-κB signaling is essential for osteoclast development. Mammals express five
NF-κB proteins that belong to two classes. Proteins of the first class do not require
processing to become activated, and consist of RelA (p65), c-Rel, and RelB. Proteins
complexes containing RelA and c-Rel are kept inactive in the cytoplasm by binding to
IκB inhibitor proteins. Upon activation of the pathway, IκB kinase (IKK) phosphorylates
IκB, leading to its degradation. IKK exists in a complex consisting of NEMO, IKKα, and
IKKβ. The second class of proteins are synthesized as large precursors, p105 and p100,
and are proteolytically processed into mature p50 and p52 NF-κB proteins, respectively.
In the canonical pathway, p50 dimerizes with RelA or c-Rel. In the alternative pathway,
p52 dimerizes with RelB (Figure 1.2) (Hayden & Ghosh, 2008; Karin & Lin, 2002).
Canonical pathway activation occurs in response to all NF-κB-activating stimuli, while
the alternative pathway is only activated by the TNF family cytokines RANKL, CD40L,
BAFF, and lymphotoxin-β. Both pathways are operant in the osteoclast (Vaira et al.,
2008), and p50-/-p52-/- mice develop osteopetrosis due to defective osteoclastognesis
(Franzoso et al., 1997; Iotsova et al., 1997).
p62, one Traf6 binding partner, has been implicated osteoclastogenesis and NFκB
signaling. Null mutation of p62 in osteoclast precursor cells causes severe impairment of
osteoclast formation in a culture system. However, p62-deficient mice exhibit no defects
unless they are challenged by osteoclastogenic stimuli such as PTH-related peptide
(PTHrP) (Duran et al., 2004). On the other hand, p62 mutations in humans are associated
with Paget's disease of bone (PDB), a genetic disorder characterized by large osteoclasts
and focal, disorganized increase of bone turnover (Laurin, Brown, Morissette, &
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Raymond, 2002). In these PDB patients, mutant p62 proteins with reduced ability to bind
ubiquitin and ubiquitin-conjugated proteins are expressed (Cavey et al., 2005). p62 is
degraded by autophagy (Bjorkoy et al., 2009), and we observe p62 accumulation in Atg5, Atg7-, and Atg16L-deficient osteoclasts, all of which have impaired autophagy.

Figure 1.2: The NFκB Pathway
Following receptor ligation, signaling to IKK proceeds through TRAF/RIP complexes,
generally in conjunction with TAK1, leading to canonical NF-κB signaling, or through
TRAFs and NIK leading to the noncanonical NFκB pathway. IKK activation results in
IκB phosphorylation and degradation in the canonical pathway or p100 processing to p52
in the noncanonical pathway. Phosphorylated NFκB dimers bind to κB DNA elements
and induce transcription of target genes.
Adapted from Matthew S. Hayden and Sankar Ghosh, Shared Principles in NF-κB
Signaling.

5

Osteopetrosis and Disorders of High Bone Density
Since this thesis aims to characterize novel molecular pathways that, when absent,
contribute to high bone density, it is useful to consider other proteins and pathways
responsible for diseases of high bone mass. Much has been learned about the critical
molecules in osteoclast biology by genetic disorder causing high bone density.
Osteopetrosis refers to disorders arising from reduced bone resorption, while disorders of
increased bone formation are simply called high bone mass syndromes (de Vernejoul &
Kornak). Osteosclerosis refers to more radio-opaque, and thus denser, bones of normal
size – in the long bones this results from trabecular thickening, and can be either
osteoblast or osteoclast related. Hyperostosis refers to cortical thickening of long bones
or enlargement of affected skull (de Vernejoul & Kornak).
Osteopetrosis is divided an autosomal dominant (ADO) adult type that is less
severe (Albers-Schonberg disease) and an autosomal recessive (ARO) type that is
typically fatal during infancy or early childhood if untreated. It is estimated around 60%
of patients with ARO have a mutation in the TCIRG1 gene encoding the α3 subunit of
the proton pump that brings H+ into the resorptive space, while around 13% have a
mutation in the CLCN7 chloride channel. The chloride channel is necessary to maintain
electroneutrality in the bone pit (Jentsch, Friedrich, Schriever, & Yamada, 1999).
Although the proton pump subunit was initially thought to be specific for the osteoclast,
it has since been found in gastric parietal cells where it is involved in gastric acid
secretion and calcium absorption, which may be responsible for a rickets-like phenotype
in children with the mutation (Schinke et al., 2009). In a smaller number of patients, the
OSTM1 gene is mutated (Chalhoub et al., 2003). These mutations lead to normal or
6

increased numbers of osteoclasts, but defective function. More recently, mutations are
described in RANKL or RANK that lead to lower numbers of osteoclasts (Guerrini et al.,
2008; Sobacchi et al., 2007).
ADO prevalence is estimated at 5 per 100,000, and 60-80% of individuals with
radiographic signs of ADO experience clinical problems. Fractures occur in 80%, most
commonly the femur; some patients have more than 10 fractures (Benichou, Laredo, &
de Vernejoul, 2000; Waguespack, Hui, Dimeglio, & Econs, 2007). These patients often
have mutations in CLCN7, which are less severe than those CLCN7 mutations causing
ARO (Cleiren et al., 2001).
Cargonic anhydrase II (CAII) is present in many tissues, including brain, kidney,
erythrocytes, cartilage, lung, and stomach. In osteoclasts, it is necessary for intracellular
production of H+ ions that are transported by the proton pump into the resorptive space
(Gay, 1996). Mutation of this enzyme leads to osteopetrosis with renal tubular acidosis
(Sly, Hewett-Emmett, Whyte, Yu, & Tashian, 1983).
A specific high bone density disorder attributed to Cathepsin K deficiency is termed
Pycnodysostosis. The first suspected case may be have been the French impressionist
painter Henri de Toulouse-Lautrec (Maroteaux & Lamy, 1965), but now over 100 cases
are described. It is autosomal recessive, leading to short stature with a relatively large
cranium. Cathepsin K is specific for the osteoclast, and is a protease secreted above the
bone to degrade its organic component (Gelb, Shi, Chapman, & Desnick, 1996).
Disorders of high bone density due to osteoblast activity are also described.
Progressive Diaphyseal Dysplasia (PDD), also known as Camurati-Engelmann disease, is
due to mutation in TGFβ1 that causes premature activation of the protein (Janssens et al.,
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2000; Janssens, ten Dijke, Ralston, Bergmann, & Van Hul, 2003). Though the protein is
ubiquitously expressed, the disease is largely limited to the skeleton. Osteopoikilosis, or
spotted bone disease, is due to LEMD3 mutation, which encodes a nuclear membrane
protein that inhibits Smad proteins, which mediate TGF-β signaling (Hellemans et al.,
2004).
The Wnt pathway is mutated in several osteoblastic bone disorders, including
Worth syndrome (LRP5 mutation) (Van Wesenbeeck et al., 2003), osteopathia striata
(WTX mutation) (Jenkins et al., 2009; Viot et al., 2002), Van Buchem disease, and
sclerosteosis (sclerostin mutation) (Balemans et al., 2002; Hamersma, Gardner, &
Beighton, 2003).
Mutation of HPGD, the main enzyme responsible for degrading prostaglandins,
causes Pachyderomperiostosis. The disorder leads to gradual enlargement of the hands
and feet, arthralgia, skin thickening, and clubbing (Seifert et al., 2009; Uppal et al.,
2008). Prostaglandins have multiple effects on osteoblasts and osteoclasts (Blackwell,
Raisz, & Pilbeam).
It is interesting to note that disorders from decreased osteoclast activity, such as
osteopetrosis or pycnodysostosis, result in frequent fractures, while disorders with
increased bone formation from either increased activity of the Wnt pathway or activating
mutation of TGF-β are not associated with fracturing. This discrepancy may be due to
decreased elasticity of the skeleton or defective repair of micro-damage resulting from
low bone remodeling. Although therapeutics that inhibit osteoclasts generally reduce
fracture rate (Iwamoto, Sato, Takeda, & Matsumoto, 2008), it is still debated whether
these drugs may also lead to pathologic fractures in some circumstances (Black et al.).
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Therapeutic inhibition of osteoclasts may still allow for cyclic periods of bone resorption
between doses, which may reduce the negative side effects resulting from complete
blockade of bone turnover.
Human genome wide association analysis (GWAS) studies are implicating an
increasing number of genes and pathways in bone homeostasis. It will be important to
determine the effect of the identified genes in the osteoclast or osteoblast, as
characterization of these novel pathways in the bone may lead to new types of drugs,
exemplified by current successful clinical trials using sclerostin and RANKL antibodies.
The following chapters implicate two new pathways in bone homeostasis, from the
molecular level to the living animal. Ultimately, knowledge of these pathways may
better our understanding of bone disease, or lead to better treatments.

9

References
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M.,
Dikkers, F. G., Hildering, P., Willems, P. J., Verheij, J. B., Lindpaintner, K.,
Vickery, B., Foernzler, D., & Van Hul, W. (2002). Identification of a 52 kb
deletion downstream of the SOST gene in patients with van Buchem disease. J
Med Genet, 39(2), 91-97.
Benichou, O. D., Laredo, J. D., & de Vernejoul, M. C. (2000). Type II autosomal
dominant osteopetrosis (Albers-Schonberg disease): clinical and radiological
manifestations in 42 patients. Bone, 26(1), 87-93.
Bjorkoy, G., Lamark, T., Pankiv, S., Overvatn, A., Brech, A., & Johansen, T. (2009).
Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol, 452,
181-197.
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C.,
Cauley, J., Leung, P. C., Boonen, S., Santora, A., de Papp, A., & Bauer, D. C.
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl
J Med, 362(19), 1761-1771.
Blackwell, K. A., Raisz, L. G., & Pilbeam, C. C. Prostaglandins in bone: bad cop, good
cop? Trends Endocrinol Metab, 21(5), 294-301.
Cavey, J. R., Ralston, S. H., Hocking, L. J., Sheppard, P. W., Ciani, B., Searle, M. S., &
Layfield, R. (2005). Loss of ubiquitin-binding associated with Paget's disease of
bone p62 (SQSTM1) mutations. J Bone Miner Res, 20(4), 619-624.
Chalhoub, N., Benachenhou, N., Rajapurohitam, V., Pata, M., Ferron, M., Frattini, A.,
Villa, A., & Vacher, J. (2003). Grey-lethal mutation induces severe malignant
autosomal recessive osteopetrosis in mouse and human. Nat Med, 9(4), 399-406.
Cleiren, E., Benichou, O., Van Hul, E., Gram, J., Bollerslev, J., Singer, F. R., Beaverson,
K., Aledo, A., Whyte, M. P., Yoneyama, T., deVernejoul, M. C., & Van Hul, W.
(2001). Albers-Schonberg disease (autosomal dominant osteopetrosis, type II)
results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet,
10(25), 2861-2867.
de Vernejoul, M. C., & Kornak, U. Heritable sclerosing bone disorders: presentation and
new molecular mechanisms. Ann N Y Acad Sci, 1192(1), 269-277.
Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C., Pickart, C.,
& Chen, Z. J. (2000). Activation of the IkappaB kinase complex by TRAF6
requires a dimeric ubiquitin-conjugating enzyme complex and a unique
polyubiquitin chain. Cell, 103(2), 351-361.
Duran, A., Serrano, M., Leitges, M., Flores, J. M., Picard, S., Brown, J. P., Moscat, J., &
Diaz-Meco, M. T. (2004). The atypical PKC-interacting protein p62 is an
important mediator of RANK-activated osteoclastogenesis. Dev Cell, 6(2), 303309.
Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi,
A., Tran, T., Boyce, B. F., & Siebenlist, U. (1997). Requirement for NF-kappaB
in osteoclast and B-cell development. Genes Dev, 11(24), 3482-3496.
Gay, C. V. (1996). Role of microscopy in elucidating the mechanism and regulation of
the osteoclast resorptive apparatus. Microsc Res Tech, 33(2), 165-170.

10

Gelb, B. D., Shi, G. P., Chapman, H. A., & Desnick, R. J. (1996). Pycnodysostosis, a
lysosomal disease caused by cathepsin K deficiency. Science, 273(5279), 12361238.
Guerrini, M. M., Sobacchi, C., Cassani, B., Abinun, M., Kilic, S. S., Pangrazio, A.,
Moratto, D., Mazzolari, E., Clayton-Smith, J., Orchard, P., Coxon, F. P., Helfrich,
M. H., Crockett, J. C., Mellis, D., Vellodi, A., Tezcan, I., Notarangelo, L. D.,
Rogers, M. J., Vezzoni, P., Villa, A., & Frattini, A. (2008). Human osteoclastpoor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK)
mutations. Am J Hum Genet, 83(1), 64-76.
Hacker, H., & Karin, M. (2006). Regulation and function of IKK and IKK-related
kinases. Sci STKE, 2006(357), re13.
Hamersma, H., Gardner, J., & Beighton, P. (2003). The natural history of sclerosteosis.
Clin Genet, 63(3), 192-197.
Hayden, M. S., & Ghosh, S. (2008). Shared principles in NF-kappaB signaling. Cell,
132(3), 344-362.
Hellemans, J., Preobrazhenska, O., Willaert, A., Debeer, P., Verdonk, P. C., Costa, T.,
Janssens, K., Menten, B., Van Roy, N., Vermeulen, S. J., Savarirayan, R., Van
Hul, W., Vanhoenacker, F., Huylebroeck, D., De Paepe, A., Naeyaert, J. M.,
Vandesompele, J., Speleman, F., Verschueren, K., Coucke, P. J., & Mortier, G. R.
(2004). Loss-of-function mutations in LEMD3 result in osteopoikilosis, BuschkeOllendorff syndrome and melorheostosis. Nat Genet, 36(11), 1213-1218.
Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., & Bravo, R. (1997). Osteopetrosis
in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med, 3(11), 1285-1289.
Iwamoto, J., Sato, Y., Takeda, T., & Matsumoto, H. (2008). Hip fracture protection by
alendronate treatment in postmenopausal women with osteoporosis: a review of
the literature. Clin Interv Aging, 3(3), 483-489.
Janssens, K., Gershoni-Baruch, R., Guanabens, N., Migone, N., Ralston, S., Bonduelle,
M., Lissens, W., Van Maldergem, L., Vanhoenacker, F., Verbruggen, L., & Van
Hul, W. (2000). Mutations in the gene encoding the latency-associated peptide of
TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet, 26(3), 273-275.
Janssens, K., ten Dijke, P., Ralston, S. H., Bergmann, C., & Van Hul, W. (2003).
Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease
lead to increased signaling by altering either activation or secretion of the mutant
protein. J Biol Chem, 278(9), 7718-7724.
Jenkins, Z. A., van Kogelenberg, M., Morgan, T., Jeffs, A., Fukuzawa, R., Pearl, E.,
Thaller, C., Hing, A. V., Porteous, M. E., Garcia-Minaur, S., Bohring, A.,
Lacombe, D., Stewart, F., Fiskerstrand, T., Bindoff, L., Berland, S., Ades, L. C.,
Tchan, M., David, A., Wilson, L. C., Hennekam, R. C., Donnai, D., Mansour, S.,
Cormier-Daire, V., & Robertson, S. P. (2009). Germline mutations in WTX cause
a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet,
41(1), 95-100.
Jentsch, T. J., Friedrich, T., Schriever, A., & Yamada, H. (1999). The CLC chloride
channel family. Pflugers Arch, 437(6), 783-795.
Kanayama, A., Seth, R. B., Sun, L., Ea, C. K., Hong, M., Shaito, A., Chiu, Y. H., Deng,
L., & Chen, Z. J. (2004). TAB2 and TAB3 activate the NF-kappaB pathway
through binding to polyubiquitin chains. Mol Cell, 15(4), 535-548.

11

Karin, M., & Lin, A. (2002). NF-kappaB at the crossroads of life and death. Nat
Immunol, 3(3), 221-227.
Kobayashi, N., Kadono, Y., Naito, A., Matsumoto, K., Yamamoto, T., Tanaka, S., &
Inoue, J. (2001). Segregation of TRAF6-mediated signaling pathways clarifies its
role in osteoclastogenesis. Embo J, 20(6), 1271-1280.
Laurin, N., Brown, J. P., Morissette, J., & Raymond, V. (2002). Recurrent mutation of
the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J
Hum Genet, 70(6), 1582-1588.
Lomaga, M. A., Yeh, W. C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., Morony, S.,
Capparelli, C., Van, G., Kaufman, S., van der Heiden, A., Itie, A., Wakeham, A.,
Khoo, W., Sasaki, T., Cao, Z., Penninger, J. M., Paige, C. J., Lacey, D. L.,
Dunstan, C. R., Boyle, W. J., Goeddel, D. V., & Mak, T. W. (1999). TRAF6
deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS
signaling. Genes Dev, 13(8), 1015-1024.
Maroteaux, P., & Lamy, M. (1965). The Malady of Toulouse-Lautrec. Jama, 191, 715717.
Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, K.,
Nakamura, K., Katsuki, M., Yamamoto, T., & Inoue, J. (1999). Severe
osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in
TRAF6-deficient mice. Genes Cells, 4(6), 353-362.
Nanci, A. (2008). Ten Cate's Oral Histology, 7th Edition. 135.
Scheidereit, C. (2006). IkappaB kinase complexes: gateways to NF-kappaB activation
and transcription. Oncogene, 25(51), 6685-6705.
Schinke, T., Schilling, A. F., Baranowsky, A., Seitz, S., Marshall, R. P., Linn, T.,
Blaeker, M., Huebner, A. K., Schulz, A., Simon, R., Gebauer, M., Priemel, M.,
Kornak, U., Perkovic, S., Barvencik, F., Beil, F. T., Del Fattore, A., Frattini, A.,
Streichert, T., Pueschel, K., Villa, A., Debatin, K. M., Rueger, J. M., Teti, A.,
Zustin, J., Sauter, G., & Amling, M. (2009). Impaired gastric acidification
negatively affects calcium homeostasis and bone mass. Nat Med, 15(6), 674-681.
Seifert, W., Beninde, J., Hoffmann, K., Lindner, T. H., Bassir, C., Aksu, F., Hubner, C.,
Verbeek, N. E., Mundlos, S., & Horn, D. (2009). HPGD mutations cause
cranioosteoarthropathy but not autosomal dominant digital clubbing. Eur J Hum
Genet, 17(12), 1570-1576.
Sly, W. S., Hewett-Emmett, D., Whyte, M. P., Yu, Y. S., & Tashian, R. E. (1983).
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal
recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral
calcification. Proc Natl Acad Sci U S A, 80(9), 2752-2756.
Sobacchi, C., Frattini, A., Guerrini, M. M., Abinun, M., Pangrazio, A., Susani, L.,
Bredius, R., Mancini, G., Cant, A., Bishop, N., Grabowski, P., Del Fattore, A.,
Messina, C., Errigo, G., Coxon, F. P., Scott, D. I., Teti, A., Rogers, M. J.,
Vezzoni, P., Villa, A., & Helfrich, M. H. (2007). Osteoclast-poor human
osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet, 39(8),
960-962.
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002). RANK-L and RANK: T cells,
bone loss, and mammalian evolution. Annu Rev Immunol, 20, 795-823.

12

Uppal, S., Diggle, C. P., Carr, I. M., Fishwick, C. W., Ahmed, M., Ibrahim, G. H.,
Helliwell, P. S., Latos-Bielenska, A., Phillips, S. E., Markham, A. F., Bennett, C.
P., & Bonthron, D. T. (2008). Mutations in 15-hydroxyprostaglandin
dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet, 40(6),
789-793.
Vaira, S., Alhawagri, M., Anwisye, I., Kitaura, H., Faccio, R., & Novack, D. V. (2008).
RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced
apoptotic JNK pathway in mice. J Clin Invest, 118(6), 2088-2097.
Van Wesenbeeck, L., Cleiren, E., Gram, J., Beals, R. K., Benichou, O., Scopelliti, D.,
Key, L., Renton, T., Bartels, C., Gong, Y., Warman, M. L., De Vernejoul, M. C.,
Bollerslev, J., & Van Hul, W. (2003). Six novel missense mutations in the LDL
receptor-related protein 5 (LRP5) gene in different conditions with an increased
bone density. Am J Hum Genet, 72(3), 763-771.
Viot, G., Lacombe, D., David, A., Mathieu, M., de Broca, A., Faivre, L., Gigarel, N.,
Munnich, A., Lyonnet, S., Le Merrer, M., & Cormier-Daire, V. (2002).
Osteopathia striata cranial sclerosis: non-random X-inactivation suggestive of Xlinked dominant inheritance. Am J Med Genet, 107(1), 1-4.
Waguespack, S. G., Hui, S. L., Dimeglio, L. A., & Econs, M. J. (2007). Autosomal
dominant osteopetrosis: clinical severity and natural history of 94 subjects with a
chloride channel 7 gene mutation. J Clin Endocrinol Metab, 92(3), 771-778.
Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J., & Chen, Z. J. (2001). TAK1 is
a ubiquitin-dependent kinase of MKK and IKK. Nature, 412(6844), 346-351.
Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M., & Choi, Y.
(1998). The TRAF family of signal transducers mediates NF-kappaB activation
by the TRANCE receptor. J Biol Chem, 273(43), 28355-28359.

13

Chapter 2: Autophagy Proteins
Mediate Lysosome Secretion and
Bone Resorption
Abstract
Osteoclasts are essential for skeletal homeostasis (Teitelbaum, 2000). These
macrophage-lineage cells function by generating a polarized space between themselves
and bone wherein skeletal matrix is degraded. This resorptive compartment is isolated
from the general extracellular space by an actin ring which encompasses the ruffled
border, a convoluted plasma membrane structure formed by its fusion with lysosomerelated vesicles containing an electrogenic H+ATPase, a chloride channel, LAMP-1, and
cathepsin K. Secreted HCl then mobilizes bone mineral while cathepsin K degrades the
collagen-rich organic bone matrix (Stenbeck, 2002; H. Zhao et al., 2008). We
determined that the two ubiquitin-like conjugation systems required for macroautophagy
are necessary for generation of the osteoclast ruffled border and the cell’s capacity to
efficiently secrete lysosomal proteins into the resorptive microenvironment both in vitro
and in vivo. These findings provide a novel role for autophagy proteins and a possible
mechanism to explain human genome wide association data suggesting a link between
the autophagy pathway and predisposition to osteoporosis (Zhang et al.).
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Introduction
Autophagy
Autophagy (more specifically macroautophagy, referred to here as autophagy) is a
pathway whereby cytoplasmic material and organelles are removed from the cell by selfdigestion. This process of self-degradation is traditionally thought of as a mechanism by
which cells may survive periods of starvation, and also serves the beneficial function of
clearing aberrant or long-lived proteins and organelles. Although basal levels of
autophagy exist in most cells, autophagy is also induced by a variety of cellular stressors,
such as starvation (Mizushima, Yamamoto, Matsui, Yoshimori, & Ohsumi, 2004),
growth factor deprivation (Lum et al., 2005), ER stress (Yorimitsu, Nair, Yang, &
Klionsky, 2006), microbial infection (Nakagawa et al., 2004), and hypoxia (Papandreou,
Lim, Laderoute, & Denko, 2008). Autophagy work was pioneered in yeast, where over
30 autophagy related genes (Atg’s) have been discovered. Many mammalian
homologues of these yeast proteins are now known, and the functions of autophagy have
expanded beyond the simple role of cell survival during starvation.

Autophagosome Formation and Maturation
The process of autophagy first involves enclosure of cytoplasmic material, most
often non-specifically, into double-membraned vesicles known as autophagosomes
(Figure 1). Autophagosomes receive proton pumps and lysosomal enzymes (in that
order, as suggested by (Dunn, 1990)) from late endosomes or multivesicular bodies, thus
slowly becoming more acidic (Berg, Fengsrud, Stromhaug, Berg, & Seglen, 1998; Dunn,
1990; Gordon, Hoyvik, & Seglen, 1992; Lawrence & Brown, 1992; Liou, Geuze, Geelen,
& Slot, 1997; Punnonen, Autio, Kaija, & Reunanen, 1993; Tooze et al., 1990). The outer
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membrane of the autophagosome eventually fuses with the lysosome, delivering its
contents still contained within the inner membrane. Thus, the inner membrane as well as
its contents are degraded by lysosomal enzymes. Lysosomal transporters then export
amino acids and other degradation products back to the cytoplasm for re-use (Mizushima,
2007).
While lysosomes and endoplasmic reticulum (ER) contain numerous integral
membrane proteins, only two have been identified on the autophagosome: Atg9 and
vacuolar membrane protein 1 (VMP1). (Fengsrud, Erichsen, Berg, Raiborg, & Seglen,
2000; Punnonen, Pihakaski, Mattila, Lounatmaa, & Hirsimaki, 1989; Rez & Meldolesi,
1980). Atg9 has six transmembrane domains and cycles between the TGN and late
endosomes in a ULK1 (yeast Atg1 homologue) dependent manner. Knocking down Atg9
impairs autophagy (Young et al., 2006), and Atg9 is proposed to deliver lipids to the
forming autophagosome (Kim, Huang, Stromhaug, & Klionsky, 2002). VMP1 localizes
predominantly to the ER, and colocalizes with LC3 and Beclin1 on autophagosome
membranes (Ropolo et al., 2007). Overexpression of VMP1 induces autophagosomes,
even under nutrient-rich conditions, and depletion using siRNA inhibits autophagosome
formation after starvation.
The source of the membrane that forms autophagosomes in mammalian cells

remains a mystery. In yeast, a unique compartment known as the pre-autophagosomal
structure forms the autophagosome (Kim et al., 2002), but such a structure has not been
identified in mammals. Conventional SNARE membrane fusion machinery, including Nethylmaleimide-sensitive factor (NSF), soluble NSF attachment protein (SNAP), and
SNAP receptors, are not needed for autophagosome formation in yeast (Ishihara et al.,
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2001; Suzuki & Ohsumi, 2007). Additionally, mutants defective in Sec12 or the Sec23–
Sec31 complex, which are needed for COPII vesicle formation and transport of vesicles
from the ER to the Golgi, have no autophagy defects (Hamasaki, Noda, & Ohsumi, 2003;
Ishihara et al., 2001). Thus, unconventional vesicle trafficking and membrane formation
mechanisms may be used during autophagosome formation.
Once autophagosomes are formed, yeast studies have shown they fail to fuse with
the vacuole (the yeast lysosome) in the absence of Ypt7 (the yeast homolog of Rab7)
(Kirisako et al., 1999), Vam3 (a syntaxin homolog) (Darsow, Rieder, & Emr, 1997),
Sec18 (yeast homolog of NSF), or Vti1, a SNARE receptor (Ishihara et al., 2001). Vti1
(Atlashkin et al., 2003) and Rab7 (Gutierrez, Munafo, Beron, & Colombo, 2004; Jager et
al., 2004) are confirmed regulators of mammalian autophagosome-lysosome fusion.

Protein Conjugating Systems
Two novel protein conjugating systems, similar to the ubiquitin conjugating system,
are utilized during autophagosome formation. These systems involve Atg12–Atg5 and
LC3–phosphatidylethanolamine (PE) conjugation, and require other proteins that act in a
similar manner to E1 and E2 enzymes in ubiquitin conjugation. The first step in
ubiquitination is formation of a high-energy bond between the C-terminus of ubiquitin
and the E1 enzyme, which uses ATP. Next, activated ubiquitin is transferred to a
cysteine on one of the E2 enzymes. Finally, E3 enzymes mediate the ligation of ubiquitin
to a lysine on a target protein (Wooten & Geetha, 2006).
In developing autophagosomes, Atg5 localizes mainly to the outer side of the
developing membrane, but is not present after sealing. In a manner similar to
ubiquitination, a lysine on Atg5 (K130) is covalently attached to a C-terminal glycine on
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Atg12 (Mizushima, Sugita, Yoshimori, & Ohsumi, 1998). In this conjugation, Atg7 acts
similar to an E1 enzyme, and Atg10 mirrors an E2 enzyme by transferring Atg12 to Atg5
(Mizushima, Yoshimori, & Ohsumi, 2003). Several Atg12–Atg5 conjugates are then
linked in a polymer by Atg16L (Mizushima, Kuma et al., 2003; Mizushima, Yoshimori et
al., 2003). This polymer is proposed to coat the developing membrane and assist in its
curvature.
Yeast Atg8 was the first autophagosome marker to be identified (Kabeya et al.,
2000), and is still used as a marker for autophagy activation. Atg8 has at least eight
mammalian homologues, which can be divided into two groups by amino acid homology:
the microtubule associated protein 1 light chain 3 (LC3) subfamily and the GABAreceptor-associated-protein (GABARAP) subfamily. In humans, three different genes
encode three highly homologous LC3 proteins, known as LC3α, LC3β, and LC3γ. Mice
have homologous LC3A and LC3B. The GABARAP family includes GABARAP, golgiassociated ATPase enhancer of 16 kDa (GATE-16) (Sagiv, Legesse-Miller, Porat, &
Elazar, 2000), GABARAPL1, and GABARAP-L3 (He et al., 2003; Xin et al., 2001).
While past autophagy research primarily focused on LC3, recent siRNA experiments
show both the LC3 and the GABARAP families are required for autophagy, but at
slightly different steps in autophagosome maturation (Weidberg et al.).
Upon autophagy induction, levels of LC3B-II correlate with elevated levels of
autophagic vesicles either by electron microscopy or immunofluorescence, whereas
LC3A-II levels do not (Klionsky et al., 2008). Here, LC3B will be referred to as LC3.
LC3 associates with both the inner and outer membranes of the autophagosome (Kabeya
et al., 2000), but dissociates from the outer membrane during maturation (Jager et al.,
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2004; Kabeya et al., 2000). The LC3 conjugation process is more involved than that of
Atg5. First, LC3 must be cleaved by Atg4 to expose a glycine residue necessary for
conjugation. LC3 is then activated by Atg7 (E1 enzyme) and transferred to Atg3 (E2
enzyme), and finally linked to phosphatidylethanolamine (PE) (Ichimura et al., 2000;
Kabeya et al., 2004; Sou, Tanida, Komatsu, Ueno, & Kominami, 2006). In yeast, the
Atg12-Atg5 conjugate acts like an E3 enzyme by enhancing the conjugation of PE to
Atg8 (yeast homologue of LC3) (Hanada et al., 2007), suggesting the Atg12-Atg5
conjugate promotes protein-lipid conjugation. Linkage of LC3 to PE results in
movement of LC3 from its cytosolic residence to the autophagosome membrane.
Membrane localized, PE-conjugated LC3 is termed LC3-II, while the cytosolic, nonconjugated LC3 is termed LC3-I, and they can be differentiated by Western (Kabeya et
al., 2000). The ratio of LC3-II/LC3-I reflects the relative amount of autophagy activity
(Kabeya et al., 2000). For normal progression of autophagy, an additional step of
deconjugation of LC3 from PE is necessary, catalyzed by Atg4 (Mizushima, Yoshimori
et al., 2003). Atg4 also processes the other LC3 mammalian homologues, including the
GABARAP family (Hemelaar, Lelyveld, Kessler, & Ploegh, 2003). The purpose of PElipidation of LC3 is suggested to aid in membrane docking and fusion, and can cause
hemifusion of membranes in vitro (Nakatogawa, Ichimura, & Ohsumi, 2007). While
LC3-II is usually found on the autophagosome membrane, it can also be recruited to
phagosomes in response to Toll-like receptor signaling, in an Atg5- and Atg7-dependent
manner. Recruitment of LC3-II to the phagosome results in phagosome fusion with lateendosomes and lysosomes (Sanjuan et al., 2007).
LC3B has been knocked out in mice, and unlike mice lacking other autophagy
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proteins (such as Atg5, Atg7, Atg3, or Beclin1), the LC3B-/- mouse survives normally
and does not exhibit defective autophagy (Cann et al., 2008), suggesting other LC3
homologues compensate.
Upstream of these conjugation pathways, autophagosome formation is commonly
initiated by the inactivation of mammalian target of Rapamycin (mTor), which leads to
activation of the class III phosphatidylinositol 3-kinase (PI3K), Vps34 (Yan & Backer,
2007). Vps34 activation is necessary for nucleation of the isolation membrane in the first
steps of autophagosome formation (Petiot, Ogier-Denis, Blommaart, Meijer, & Codogno,
2000).

Autophagy and Secretion
The autophagy pathway is implicated in secretion in a small number of cell types.
Mice hypomorphic for the autophagy protein Atg16L have a defect in paneth cells
resembling that of human subjects with an Atg16L polymorphism making them more
susceptible to Chron’s disease. These cells appear constipated with lysozyme, have
abnormal distribution of the enzyme within the cytoplasm, and are relatively absent of the
enzyme in the intestinal lumen, suggesting impaired secretion of lysozyme in these cells
(Cadwell et al., 2008). In Saccharomyces cerevisiae and Pichia pastoris yeast, secretion
of the acyl-coA binding protein Acb1 does not involve conventional secretion through the
ER, but rather is enclosed in an autophagosome which fuses with recycling endosomes to
form a multivesicular body, which then fuses with the plasma membrane in a SNARE
protein dependent manner (Duran, Anjard, Stefan, Loomis, & Malhotra, ; Manjithaya,
Anjard, Loomis, & Subramani). Other secretory cells, including melanocytes and β-cells
of the pancrease, are functionally affected by deletion of autophagy genes, although
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direct involvement of autophagy proteins in the secretory process is not shown in these
cells (Ebato et al., 2008; Ganesan et al., 2008; Jung et al., 2008).

The Osteoclast Ruffled Border and Cytoskeleton
Two of the most striking and characteristic morphologic features of the osteoclast
are the actin ring and ruffled border. The actin ring, literally a ring of actin filaments that
forms over a tight, circular attachment to the bone, is necessary for bone resorption
(Lakkakorpi, Tuukkanen, Hentunen, Jarvelin, & Vaananen, 1989). The membrane
beneath the actin ring becomes convoluted due to a large number of vesicles fusing with
the plasma membrane in this region, forming a “ruffled border.” Degraded bone matrix
is thought to transcytose from the ruffled border to the opposite end of the osteoclast,
allowing for its removal (Nesbitt & Horton, 1997; Salo, Lehenkari, Mulari, Metsikko, &
Vaananen, 1997).
Neither the actin ring nor ruffled border form in osteoclasts grown on plastic or
glass surfaces, suggesting matrix interactions are critical for osteoclast activation.
Cell/matrix interactions are commonly mediated by integrins, and the major integrin in
the mature osteoclast is αvβ3 (Inoue, Namba, Chappel, Teitelbaum, & Ross, 1998),
which binds collagen, vitronectin, and other bone matrix proteins. Osteoclasts cultured
from mice lacking αvβ3 form actin rings but have abnormal ruffled borders and shallow
resorption pits (McHugh et al., 2000). αvβ3 leads to cytoskeletal rearrangement in the
osteoclast by activating RhoA and Rac GTPases from their GDP- to GTP-bound forms
(Faccio, Takeshita, Zallone, Ross, & Teitelbaum, 2003). Additionally, the tyrosine
kinase c-src associates with the integrin and becomes activated upon integrin ligation. Csrc then phosphorylates syk kinase, which is recruited to the activated integrin (Miyazaki
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et al., 2004; Schwartzberg et al., 1997). Syk ultimately activates the Rac GTPase through
Vav3, a Rac-specific guanine nucleotide exchange factor (GEF) in the osteoclast (Faccio
et al., 2005).

Lysosome Secretion
Lysosomes are specialized organelles for intracellular protein degradation, but a
small number of cells secrete their lysosomes for extracellular purposes. Some have
suggested secretory lysosomes are specialized and different from those mediating protein
degradation. This idea is challenged by the observation that all lysosomes can fuse with
the plasma membrane in response to membrane damage (Andrews, 2000; Rodriguez,
Webster, Ortego, & Andrews, 1997). This fusion is mediated by synaptotagmin VIIa and
may repair plasma membrane damage and dispose of surplus lysosomal membrane
(Martinez et al., 2000). In contrast, some cells with secretory lysosomes possess specific
proteins that regulate their secretion, suggesting certain markers may exist that
distinguish secretory from degradative lysosomes. For example, in melanocytes, the
lysosome-like melanosome is bound to Rab27a, which localizes the melanosome to the
plasma membrane in a myosin-V (an actin molecular motor) dependent manner (Wu et
al., 2002). In the osteoclast, secretory lysosomes contribute to generating the ruffled
membrane, but specific markers of secretory lysosomes are not known. Rab7, which in
other cells is important in late endosome/lysosome trafficking, may be the most likely
candidate since it is localized at (Palokangas, Mulari, & Vaananen, 1997), and likely
important for trafficking material to, the ruffled border (Zhao, Laitala-Leinonen, Parikka,
& Vaananen, 2001).
The resorption lacuna, enclosed by the ruffled border and bone surface, is
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reminiscent of an “external lysosome.” LAMP1 and LAMP2, two integral membrane
proteins of the lysosome, are enriched at the ruffled border (Palokangas et al., 1997).
Cathepsins are lysosomal proteinases, and Cathepsin K is found exclusively in the
osteoclast, where it is necessary for bone matrix degradation (Drake et al., 1996).
Cathepsin K is found concentrated at the ruffled border and resorption lacuna (Yamaza et
al., 1998). Deficiency of Cathepsin K in humans causes pycnodysostosis, a disease
characterized by short long bones, craniofacial malformations, and malocclusion of the
teeth, all due to osteoclast dysfunction (de Vernejoul & Benichou, 2001). The large area
of the ruffled border as well as the speed at which a resorption pit is formed in vitro
suggest the ruffled border is derived by exocytosis of lysosomes, endosomes, or other
storage granule-like structures. Thus, much attention has been given to the role of
lysosomes, especially “secretory lysosomes,” in osteoclast function.
Importantly, autophagy loss is associated to lysosome dysfunction in intestinal cells
deficient of Atg5, Atg16L, or Atg7 (Cadwell, Patel, Komatsu, Virgin, & Stappenbeck,
2009). Human polymorphisms in Atg16L that reduce its function are associated with
similar lysosome defects in intestinal Paneth cells, and this dysfunction is associated with
Crohn’s disease. In patients with this polymorphism, and in mice lacking these genes,
lysozyme mislocalizes throughout the Paneth cell and the cell is dysfunctional. The
rationale for the mislocalization is unclear, as this is a novel, but clinically important role
for autophagy proteins. We find the osteoclast parallels the Paneth cell in several ways; a
lysosomal enzyme (CatK) is mislocalized within the cell, the cells are dysfunctional, and
in mice this leads to a disease phenotype (in this case, protection from osteoporosis).
However, unlike the Paneth cell, osteoclasts can be cultured in large quantities and
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manipulated in vitro. Thus, the osteoclast may provide a system to study the mechanisms
behind this novel role for autophagy proteins. Furthermore, our results suggest an
osteoclast-specific autophagy inhibitor may be an effective treatment for osteoporosis.
Atg5 and Atg7 knockout mice die within the first day of life (Komatsu et al., 2005;
Kuma et al., 2004). Thus, after visualizing LC3 within the cell, we examined the bones
and osteoclasts of mice containing loxP-flanked Atg5 or Atg7 genes (Hara et al., 2006;
Komatsu et al., 2005) bred to mice expressing the Cre recombinase under control of
Lysozyme-M, a monocyte/granulocyte specific promoter (Clausen, Burkhardt, Reith,
Renkawitz, & Forster, 1999).
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Results
Lipidated LC3 Localizes to the Osteoclast Ruffled Border in an Atg5 Dependent
Process
To determine LC3 localization, we cultured bone marrow macrophages of GFPLC3 transgenic mice (Mizushima et al., 2004) on bone fragments to generate osteoclasts.
By confocal microscopy, GFP-LC3 was found in concentrated in the actin ring in a
number of osteoclasts (Figure 2.1). Cathepsin K co-localized within the actin ring
confirming that GFP-LC3 is within the resorptive microenvironment (Yamaza et al.,
1998) (Figure 2.1). We did not observe GFP-LC3/cathepsin K co-localization external to
the confines of the actin ring, suggesting that LC3 is not on the same vesicles as those
containing Cathepsin K. To test whether Thus, in addition to its known residence on
autophagosomes and aggregates of cytoplasmic proteins (Kuma, Matsui, & Mizushima,
2007), LC3 transits to the region of the ruffled border in bone-residing osteoclasts.
LC3 Associates Directly with the Ruffled Border
To better characterize the LC3-containing compartment of the osteoclast, we
performed iodixanol density gradient fractionation (Gille & Nohl, 2000; Graham, Ford, &
Rickwood, 1994) of osteoclasts grown on bone powder. Previously this method was used
to demonstrate ruffled-border components resolved at the densest level of the gradient
(H. Zhao et al., 2008).

In both Atg5flox/flox-LyzM-Cre+ and Atg5flox/flox samples, the

densest fractions contained ruffled border and plasma membrane proteins flotillin and
β3s integrin. In Atg5flox/flox samples, LC3 was also found exclusively at this location,
while Atg5flox/flox-LyzM-Cre+ osteoclasts contained a significant amount of LC3 in a less
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dense, perhaps cytoplasmic fraction (Figure 2.2). These results are consistent with IF
data suggesting LC3 is present in the ruffled border compartment in Atg5flox/flox but not
Atg5flox/flox-LyzM-Cre+ osteoclasts, but it does not identify the specific membranes
containing the LC3.
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We considered the possibility that LC3 localization at the ruffled border might
reflect the accumulation of autophagosomes in this area. ImmunoEM on bone-residing
GFP-LC3 transgenic osteoclasts revealed that LC3 polarized toward the bone-apposed
membrane in osteoclasts that had not yet initiated bone resorption or ruffled border
formation (Figure 2.3). Importantly, in osteoclasts with developed ruffled borders, LC3
was found directly associated with the ruffled border domain of the plasma membrane in
the absence of autophagosomes (Figure 2.4).
During autophagy, LC3 is localized to autophagosomes after LC3I is conjugated
to PE on glycine 120 generating LC3II. To determine the role of PE conjugation in LC3
localization to the resorptive microenvironment, we retrovirally transduced osteoclasts
with either wild-type GFP-LC3 or the non-conjugatable mutant GFP-LC3G120A. While
WT GFP-LC3 was constrained by actin rings in 30% of osteoclasts, this occurred in less
than 10% of cells transduced with GFP-LC3G120A (Figure 2.5). Thus lipidation of LC3 on
glycine 120 is required for efficient transport of LC3 to the resorptive microenvironment.
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Figure 2.4: LC3 Directly Associates with the Ruffled Border
A) High magnification of the ruffled border of a GFP-LC3 transgenic osteoclast
grown on bone, immunostained with gold labeled anti-GFP, demonstrates
LC3 associates directly with the ruffled border membrane, independent
of autophagosomes or other organelles. B) GFP-LC3 is also seen on
autophagosomes scattered throughout the osteoclast cytoplasm.
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LC3II is targeted to specific locations by a complex of proteins including Atg5
covalently conjugated to Atg12 (Checroun, Wehrly, Fischer, Hayes, & Celli, 2006). Atg5
is required for the lipidation and binding of LC3 to autophagosomes and phagosomes
(Mizushima et al., 2001; Sanjuan et al., 2007). To determine the role of Atg5 in LC3II

localization in osteoclasts we bred Atg5flox/flox mice to those expressing the Cre
recombinase under control of the lysozyme M promoter (LyzM-Cre) which is
constitutively active in myeloid lineage cells, including osteoclasts (Clausen et al., 1999;
Z. Zhao et al., 2008). Western blot of Atg5flox/flox-LyzM-Cre+ osteoclasts revealed
efficient excision of Atg5 and inhibition of autophagy as manifest by accumulation of
p62 and decreased LC3II (Figure 2.6). Atg5flox/flox-LyzM-Cre+ bone marrow cells
exhibited a slight delay in osteoclast formation, but by day five formed normal numbers
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of bone resorptive polykaryons (Figure 2.7). The delay in osteoclast formation may be
due to a slight defect of proliferation of precursors (Figure 2.8). Apoptosis levels,
measured by anti-histone ELISA death detection kit, were equivalent (Figure 2.9). We
observed no difference between Atg5flox/flox-LyzM-Cre+ and Atg5flox/flox cells in the
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expression of osteoclast differentiation markers (Figure 2.10), the packaging of cathepsin
K (Figure 2.10), the average number of nuclei per osteoclast (Figure 2.11), or their ability
to form actin rings on bone (Figure 2.12). Therefore Atg5 is not required for osteoclast
formation or polarization of the cell’s fibrillar actin.
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Figure 2.10: Atg5-Deficient Osteoclasts Differentiate Normally
A) Immunoblot of markers of osteoclast differentiation in Atg5flox/flox and
Atg5flox/flox-LyzM-Cre+ bone marrow macrophages treated with M-CSF
and RANK ligand. B) Ultrathin cryosections of Atg5flox/flox (upper panel)
and Atg5flox/flox-LyzM-Cre+ (lower panel) osteoclasts immunogold labeled
for cathepsin K (10 nm gold particles). Depletion of Atg5 does not result in an
altered subcellular localization of cathepsin K, representative images from
two experiments. E, endosome; PM, plasma membrane; SL, secretory lysosome
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We next transduced Atg5flox/flox-LyzM-Cre+ or Atg5flox/flox cells with GFP-LC3,
which localized to the ruffled border in the control but not Atg5-deficient osteoclasts
(Figure 2.13, Figure 2.14). Hence, Atg5-dependent lipid conjugation is required for LC3
transport to the resorptive microenvironment.
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Atg5 and Atg7 are Necessary for Efficient Bone Resorption
Since these data suggested that autophagy-associated ubiquitin-like conjugation
systems might participate in osteoclast secretory function, we assessed the bone
resorptive capacity of Atg5-deficient cells.

We cultured Atg5flox/flox-LyzM-Cre+ or

Atg5flox/flox osteoclasts on bone for six days and measured resorption pits by confocal
microscopy (Salo et al., 1997). Atg5 was critical for efficient bone resorption as pits
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formed by Atg5flox/flox osteoclasts were approximately twofold deeper than those
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excavated by Atg5flox/flox-LyzM-Cre+ cells (Figure 2.15, Figure 2.16). Bone pit volume
was similarly reduced (Figure 2.17).
To determine if other essential autophagy proteins are important for bone
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resorption, we deleted Atg7, which is required for the conjugation of Atg5 to Atg12, from
osteoclasts (Komatsu et al., 2005; Z. Zhao et al., 2008; Zhao et al., 2007).
Immunoblotting of lysates of Atg7flox/flox-LyzM-Cre+ osteoclasts revealed a substantial
reduction in Atg7 and inhibition of LC3-I to LC3-II conversion (Figure 2.18, Figure

2.19). Similar to those lacking Atg5, the depth of bone pits generated by Atg7-deficient
osteoclasts was decreased (Figure 2.20). The magnitude of bone pit depth reduction
consequent to Atg5 or Atg7 deficiency was similar to that observed with deletion of
cathepsin K or the αvβ3 integrin, which are required for efficient osteoclast resorptive
function (McHugh et al., 2000; Saftig et al., 1998).
40

Atg5 and Atg7 are Required for Lysosomal Secretion at the Ruffled Border
Bone resorption requires secretion of matrix-degrading molecules at the ruffled
border suggesting that the shallow pits generated by Atg5-deficient osteoclasts may
reflect defective focal secretion. We therefore examined this resorptive organelle in more
detail by assessing the localization of lysosomal proteins. We selected LAMP1 as an
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integral membrane protein in the lysosome-like vesicles whose contents are secreted by
osteoclasts and cathepsin K as a lysosomal protease delivered by these vesicles to the
resorptive microenvironment (Akamine et al., 1993; Maeda, Akasaki, Yoshimine,
Akamine, & Yamamoto, 1999; Palokangas et al., 1997; Yamaza et al., 1998). Cathepsin
K and LAMP1 localized principally within the actin ring in 50-60% of Atg5flox/flox
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osteoclasts (Figure 2.21, Figure 2.22) but only 20-30% of Atg5flox/flox-LyzM-Cre+
osteoclasts (Figure 2.22). Transport of Cathepsin K to the resorptive microenvironment
was also defective in Atg7-deficient osteoclasts (Figure 2.23).
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We considered possible explanations for the role of autophagy proteins in the
secretory function of osteoclasts other than a direct role in secretion from the ruffled
border. The quantities of pro-cathepsin K and its mature active form were normal in
plastic-grown Atg5-deficient osteoclasts indicating proper synthesis and activation of this
lysosomal enzyme (Rieman et al., 2001) (Figure 2.24). Further, constitutive and receptormediated endocytosis which occurs in the resorptive environment, as analyzed by
fluorescent dextran (Figure 2.25) or transferrin uptake (Figure 2.26) (Palokangas et al;
Stenbeck and Horton, Endocytic trafficking in actively resorbing osteoclasts), were
equivalent in Atg5flox/flox-LyzM-Cre+ and Atg5flox/flox osteoclasts on bone. Autophagy gene
deficiency disrupts intracellular membranes and mitochondria in hepatocytes and Paneth
cells (Cadwell et al., 2008; Komatsu et al., 2005). However, analysis of osteoclasts by
electron microscopy revealed no morphological abnormalities of mitochondria or
intracellular membranes in Atg5-deficient osteoclasts (not shown). These data are
consistent with a selective role for autophagy proteins in the secretory process that occurs
at the ruffled border.
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Given that the ruffled border is derived from fusion of lysosome-like vesicles,
suggests Atg5 deficiency would result in defective formation of this resorptive organelle

(Helfrich & Gerritsen, 2001; Josephsen et al., 2009; Kornak et al., 2001; McHugh et al.,
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2000; Reinholt et al., 1999). We therefore ultrastructurally examined the ruffled borders
of osteoclasts in tibea of Atg5flox/flox and Atg5flox/flox-LyzM-Cre+ mice, grading them
independently by two genotype-blinded observers as absent, immature, or mature (Figure
2.27). Atg5flox/flox-LyzM-Cre+ osteoclasts were more than ten-fold predisposed to lack
sealing-zone (i.e. actin ring)-adjacent ruffled borders than those of Atg5flox/flox mice
(Figure 2.28). When present, convoluted membranes were less likely to be mature in
Atg5flox/flox-LyzM-Cre+ osteoclasts.

These in vivo observations suggest that Atg5

participates in generating the ruffled border via fusion of lysosome-like vesicles with the
bone-apposed plasma membrane.

Atg5-Atg12 Conjugation and Atg4b are Necessary for Efficient Lysosome
Loalization and Bone Resorption
To determine if the role of Atg5 in osteoclast secretory function requires
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conjugation to Atg12, as is true for its role in macroautophagy, we expressed wild-type
Atg5 or Atg5 with its Atg12-conjugating lysine mutated to arginine (Hamacher-Brady et
al., 2007; Mizushima et al., 2001) in Atg5flox/flox-LyzM-Cre+ or Atg5flox/flox osteoclasts.
Atg5, but not Atg5K130R, complexed with Atg12. Moreover, only wild-type Atg5
normalized LC3II generation (Figure 2.29), cathepsin K localization (Figure 2.30), and
bone pit formation (Firgure 2.31) in Atg5flox/flox-LyzM-Cre+ cells.

Hence the Atg5-Atg12 conjugate regulates osteoclast secretory function. Interestingly,
expression of Atg5K130R in Atg5flox/flox osteoclasts decreased bone pit depth and prompted
abnormal cathepsin K localization, consistent with a dominant-negative function noted in
other cells (Hamacher-Brady et al., 2007; Pyo et al., 2005).
The Atg5-Atg12 complex is important for LC3 conjugation, but along with Atg7,
these proteins may have other activities (Jounai et al., 2007; Virgin & Levine, 2009).
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Atg7-independent autophagy is implicated in mitochondrial clearance from reticulocytes
(Zhang et al., 2009), and Ulk-1 (a mammalian homologue of Atg1) is required for both
reticulocyte clearance of mitochondria (Kundu et al., 2008) and, along with Beclin-1, for
Atg5/Atg7- independent autophagy (Nishida et al., 2009). Therefore, we retrovirally
transduced osteoclasts with a mutant form of Atg4B (Atg4BC74A) which binds LC3 and
blocks its conjugation to PE (Figure 2.32). Importantly, Atg4BC74A inhibits autophagy

without disrupting formation of the Atg5-Atg12 conjugate (Fujita, Hayashi-Nishino et al.,
2008).

Atg4BC74A expression reduced bone pit formation (Figure 2.33) and caused

mislocalization of cathepsin K (Figure 2.34). Expression of this construct in GFP-LC3
osteoclasts also inhibited LC3 localization to the ruffled border (Figure 2.35, Figure 2.36
A). These data indicate that LC3 lipidation and the Atg5-Atg12 complex are both
required for efficient osteoclast secretion.
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Figure 2.36: A) Dominant Negative Atg4b Impairs LC3 Localization to the Actin
Ring. B, C) Atg5 is necessary for Rab7 to localize to the ruffled border
Quantification of percentage of cells with GFP-LC3 localized in the actin ring of control
or Atg4b-C74A transduced GFP-LC3 osteoclasts, 1 of 2 experiments shown. B, C) Confocal
images of bone-residing Atg5flox/flox and Atg5flox/flox-LyzM-Cre+ osteoclasts. Immunostaining of actin (red) and Rab7 (green) shows localization of Rab7 within the actin ring in
Atg5flox/flox that is diminished in Atg5flox/flox-LyzM-Cre+ osteoclasts, representative of
four experiments, cell perimeters outlined in white.

Rab7 generates the ruffled border, modulates bone resorption and promotes
autophagosome maturation (Zhao et al., 2001; Gutierrez et al., 2004; Harrison et al.,
2003; Jager et al., 2004; Yamaguchi et al., 2009; Tabata et al., 2010). Indicating that

53

ruffled border formation by this small GTPase is Atg5-dependent, Rab7 appeared at the
ruffled border in 60% of control osteoclasts, but only 16% of those lacking Atg5 (Figure
2.36 B). In comparison, Rab7 localization to the area surrounding the actin ring does not
require Atg5 (Figure 2.36 B, C).
Atg5 Loss in the Osteoclast Protects from Estrogen-deficiency Osteoporosis in vivo
To mirror the most common human cause of osteoporosis, namely estrogen
deficiency, we tested the effect of osteoclast Atg5 deletion on skeletal mass after
ovariectomy. Analysis of trabecular bone volume by micro-CT established a small but
significant increase in naïve Atg5flox/flox-LyzM-Cre+ versus Atg5flox/flox mice after eight
weeks (Figure 2.37), and a slightly larger increase after 9 months (Figure 2.38).
Importantly, absence of Atg5 in osteoclasts reduced ovariectomy-induced bone loss by
approximately 50% (Figure 2.39). Confirming global suppression of bone resorption,
serum levels of c-telopeptide of type I collagen (CTx) was reduced two weeks after
ovariectomy (Figure 2.40). Thus, Atg5 and LC3B regulate osteoclast function, in vitro
and in vivo.
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Discussion
Our data establish an unexpected role of the ubiquitin-like conjugation systems
required for autophagy in the bone resorptive process. Atg5, Atg7, and LC3 (based on
data from expression of a dominant negative form of Atg4B), participate in generating
the most important functional organelle of the osteoclast, its ruffled membrane. This
organelle is formed by fusion of lysosome-like vesicles to the bone-apposed plasma
membrane, mirroring that of autophagosomes and phagosomes, containing Toll-like
receptor ligands (Sanjuan et al., 2007), to lysosomes. Each process involves the ubiquitinlike conjugation apparatus essential for macroautophagy (Figure 2.41). Taken together
with human genetic data (Pan et al., ; Zhang et al.), an immediate practical implication of
our findings is the candidacy of autophagy proteins as anti-resorptive targets for
treatment of pathological bone loss. Importantly our findings also indicate that
therapeutic modulation of these genes, or the autophagy pathway, for other purposes,
may impact the skeleton and thus should be accompanied by evaluation of bone density.
Molecularly, our data suggest autophagy machinery may enjoy a general role in targeting
lysosomes to specific intracellular membranes.
Traditionally, autophagy has been described as a pathway involving two
ubiquitin-like conjugation pathways that leads to autophagosome formation and protein
degradation. A major implication of our findings is that the cascade of “autophagy”
proteins may mediate effects independent of the autophagosome. Unfortunately, no
proteins have been identified that explicitly mediate autophagosome formation or
function without affecting the rest of the pathway. Atg9 is an integral membrane protein
thought to deliver membrane to the autophagosome, but unfortunately even Atg9 is
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important for LC3 conjugation (Matsunaga et al., 2009; Yamada et al., 2005; Zhong et
al., 2009).

Figure 2.41: Model of Autophagy Machinery in the Osteoclast
LC3 localizes to the bone-apposed plasma membrane upon lipidation to PE.
Proper localization requires the autophagy proteins Atg5 and Atg7, as well
as Atg5-Atg12 conjugation. Rab7 also localizes to the ruffled border in an
Atg5-dependent manner. At the plasma membrane, LC3 promotes
trafficking, tethering or fusion of lysosomal vesicles, promoting ruffled
border formation, secretion of Cathepsin K, and bone resorption.
Although LC3 becomes lipidated and associated with the bone apposed resorptive
membrane, its exact function here is unclear. ImmunoEM showing lack of LC3 on
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lysosomal membranes or on autophagosomes near the ruffled border help exclude the
possibility that LC3 associates with either lysosomes or autophagosomes that fuse with
the plasma membrane. Direct fusion of autophagosomes with the membrane would also
result in lipids or cytosolic components in the resorptive space, which we do not observe.
LC3 at the resorptive membrane may directly mediate fusion of incoming lysosomes, as
it does with autophagsome and with membranes in vitro. Alternatively, it may tether
secretory vesicles near the membrane, or may serve as an adaptor for other proteins, such
as Synaptotagmin VII (H. Zhao et al., 2008), that must localize here to mediate fusion. To
distinguish between adaptor protein or membrane fusion/tethering functions, it would be
interesting to make corresponding mutations described in Atg8 (the yeast LC3
homologue) that abolish its membrane hemifusion function without affecting its PE
lipidation (Nakatogawa et al., 2007). These proteins, in addition to WT, could be overexpressed to see if they restore CatK localization and bone pit resorption.
It is still not known why LC3 associates specifically with the autophagosome and
not other organelles, and an unanswered question here is what targets LC3 to the ruffled
border rather than surrounding membrane. One possibility is that the distinct lipid
composition of the bone-apposed plasma membrane attracts appropriate Atg proteins,
which then recruit LC3. Forced localization of Atg16L to the plasma membrane using a
prenylation motif promoted recruitment of LC3-II to this site (Fujita, Itoh et al., 2008).
The prenylated Atg16L promoted GFP-LC3 conjugation to PE independent of starvation.
Lipidation was also insensitive to wortmannin, which inhibits PI3K and traditional
autophagy, suggesting that the main function of PI3P formation by the type III PI3K is to
localize the Atg16L complex to the PI3P-rich isolation membrane of the autophagosome.

60

Although PI3K is already known to be important for osteoclast activation, it would be
interesting to see if the ruffled border is indeed concentrated in PI3P.
In any given culture of wild type osteoclasts on bone, my experience is that 50%
or more of the cells will exhibit CatK and Lamp1 localized within the actin ring.
However, we observed LC3 localized in less than 30% of osteoclasts. Nearly every
osteoclast that had LC3 within the actin ring also had CatK. There are three possible
explanations for the relative abundance of CatK at this area relative to LC3. One is a
sensitivity issue; perhaps LC3, even when GFP tagged and transgenically or retrovirally
expressed, is less easily visualized than CatK. The second is a kinetics issue; perhaps
LC3 only initiates or enhances the fusion process, or perhaps it dissipates more quickly
than the CatK. Finally, vesicles that carry CatK or Lamp1 may have parallel pathways
for reaching and fusing with the ruffled border that do not rely on LC3. One way to
address the kinetics issue would be live cell imaging on bone. GFP-LC3 transgenic
macrophages could be transduced with RFP-actin, differentiated to osteoclasts, then
given a lysotracker dye and imaged on bone substrate over time to visualize the order of
events. I would expect to see actin ring formation first, followed GFP-LC3 localization
within the actin ring, and finally lysososome accumulation within the area, leading to
lysosome fusion with the membrane and bone resorption. One caveat of this experiment
is that even transduced GFP-LC3 is difficult to visualize; we had to immunostain GFPLC3 transgenic cells with FITC conjugated anti-GFP antibody to see the fluorescence.
All of our studies, like many in the past, rely entirely on GFP-LC3 rather than
endogenous LC3. There are three caveats to this approach. One is that over-expressed
GFP–LC3 can be incorporated into protein aggregates independent of autophagy.
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Fortunately, although we observe LC3 enrichment at the ruffled border, it does not
appear in clumps or aggregates. A second is that transfection procedures used to
introduce GFP-LC3 can activate autophagy (Klionsky et al., 2008). We also observe
transduction procedures affect osteoclast activity, which is why all experiments had
control vector transductions. Finally, GFP-LC3 simply may not behave the same as
endogenous LC3. GFP-LC3 has been used rather than endogenous LC3 in the majority of
previous autophagy studies for convenience, and besides non-specific aggregation the
GFP tag has not been reported to affect the protein’s function, but we still cannot rule out
it has an artificial effect.
One implication of our findings is that drugs or proteins that affect autophagy
may also affect the bone. In many cases, autophagy modifiers are already known to have
skeletal effects. Consistent with autophagy proteins mediating osteoclast secretory
activity, Rab7 is necessary for both autophagosome formation and fusion of
autophagosomes with lysosomes (Gutierrez et al., 2004; Jager et al., 2004), as well as for
targeting the hydrogen pump to the ruffled border for bone resorption (Zhao et al., 2001).
Hypoxia activates autophagy (Semenza, ; Tracy et al., 2007). Rab7 is also associated
with osteoporosis and osteoclast activation in vitro (Knowles & Athanasou, 2009; Miller
et al., 2006). Wortmannin, an inhibitor of PI3K and autophagy (Blommaart, Krause,
Schellens, Vreeling-Sindelarova, & Meijer, 1997), blocks bone resorption (Nakamura et
al., 1995). The same may be true of other PI3-kinase inhibitors used to inhibit
autophagy, such as 3-methyladenine and wortmannin (Seglen & Gordon, 1982), but these
drugs likely also affect osteoclast activity independently (Chen et al., 2004).
Hydroxychloroquine, another autophagy inhibitor, increases bone density (Stapley,
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2001), and is a common treatment for arthritis (Bingham & Miner, 2007). However,
since this drug increase lysosomal pH leading to less protease activity, one would expect
it to inhibit osteoclast bone resorption by direct lysosomal action. One would expect the
same of the autophagy inhibitor Bafilomycin A1, which inhibits fusion of
autophagosomes with both endosomes and lysosomes (Mousavi et al., 2001; Yamamoto
et al., 1998), but also inhibits the Na+H+ pump on the lysosome. Thus, molecules and
proteins known to activate or inhibit autophagy have consistent effects on bone
resorption, but all of these mediators are non-specific.
One of the initial reasons I was drawn to study autophagy in the osteoclast was
the connection between autophagy, the adaptor protein p62, and the osteoclastic disorder
known as Paget’s disease of bone. Paget’s is a painful bone disease characterized by
focal lytic areas of increased bone turnover, where the osteoclasts are oversized and
overactive. Osteoblasts react by increasing their activity, leading to high levels of
alkaline phosphatase, and formation of disorganized, weak bone prone to fracture
(Laurin, Brown, Morissette, & Raymond, 2002). It is one of the more common bone
diseases among Caucasians, with 3% affected over the age of 50 (Helfrich & Hocking,
2008). The most common genetic mutation found in Paget’s disease patients is in p62.
p62 interacts with ubiquitinated proteins to mediate aggregate formation, but also binds
LC3, and is thus thought to target ubiquitinated aggregates to the autophagosome
(Komatsu & Ichimura, ; Komatsu et al., 2007). In the osteoclast and other cells, p62 also
mediates Traf6 and NFkB activation as a molecular scaffolding protein (Chamoux et al.,
2009; Duran et al., 2004; Yip, Feng, Pavlos, Zheng, & Xu, 2006). Null mutation of p62
in osteoclast precursor cells causes severe impairment of osteoclast formation in a culture
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system. However, p62-deficient mice exhibit no defects unless they are challenged by
osteoclastogenic stimuli such as PTH-related peptide (PTHrP) (Duran et al., 2004). It is
possible the secretion phenotype we observe in autophagy deficient osteoclasts is related
to buildup of protein aggregates that impair cellular function. To test this hypothesis, it
would be interesting to see if loss of p62 rescues the phenotype, by breeding p62-/- mice
with Atg5flox/flox-LyzM-Cre+ mice, or using p62 siRNA. This method has worked in
hepatocytes, where loss of p62 reduces the number of protein aggregates in autophagy
deficient cells and restores cellular function (Komatsu et al., 2007). Alternatively, it is
possible LC3 functions to bind p62 and localize it to the ruffled border where it has a
separate function, but in my p62 immunofluorescence studies, I did not find p62 localized
within the actin ring in WT cells.
In the course of this project, before either of the two papers were published using
GWAS to show the autophagy pathway is significantly associated with bone phenotypes
in humans, we analyzed a similar databank of polymorphisms and tested for their link to
bone mineral density. Although individually none of the autophagy proteins were
significantly associated, we noted that most of them were close, which is probably why
the two other groups used a pathway-based analysis to achieve significance. In the study
of height variability (Pan et al.), genes most significantly associated were Atg5, Atg12,
Atg4, Atg3, Beclin1, GABARAPL1, and GABARAPL2. In young individuals, height is
influenced by chondrocytes, osteoblasts, and osteoclasts as bone modeling occurs.
Additionally, it is estimated that patients lose an average of 4.5 cm between 40 and 70
years old (Briot, Legrand, Pouchain, Monnier, & Roux), and height loss is predictive of
fragility fractures and osteoporosis (Gunnes, Lehmann, Mellstrom, & Johnell, 1996;
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Siminoski et al., 2005). Since the average age of patients in the GWAS study for height
was over 70, both bone growth during youth and bone loss during age are relevant.
Although both depend on osteoclast activity, effects of autophagy on osteoblast and
chondrocytes should also be considered in future studies (Srinivas & Shapiro, 2006).

Methods
Mice The generation of Atg5flox/flox, Atg7flox/flox, Atg5flox/flox-LyzM-Cre+, and GFP-LC3
mice has been previously reported(Hara et al., 2006; Komatsu et al., 2005; Mizushima et
al., 2004; Z. Zhao et al., 2008). To generate Atg7flox/flox-LyzM-Cre+ mice, we bred
Atg7flox/flox mice to mice expressing the Cre recombinase from the Lysozyme M locus
(strain #004781, Jackson Laboratory, Bar Harbor, ME).

Atg5flox/flox, Atg7flox/flox,

Atg5flox/flox-LyzM-Cre+ mice were genotyped as described(Stephenson et al., 2009).
GFP-LC3

mice

were

genotyped

with

primers

GFP-1:

5′-

TCCTGCTGGAGTTCGTGACCG-3′ and LC3: 5′-TTGCGAATTCTCAGCCGTCTTCA
TCTCTCTCGC-3′ using PCR [94°C(4 min); 35 cycles of 94°C (30 sec), 57°C (30 sec),
72°C (1 min); 72°C (5 min)]. Mice were maintained at Washington University School of
Medicine in accordance with institutional policies for animal care and usage.

Cell culture Osteoclasts were grown in alpha10 media, containing alpha-MEM
(Sigma Aldrich, St. Louis, MO), 10% fetal calf serum (Hyclone, Waltham, MA),
100U/mL penicillin and 100ug/mL streptomycin. Plat-E retrovirus packaging cells were
purchased from Cell Biolabs, Inc. (San Diego, CA) and maintained in DMEM media
(Cellgro, Manassas, VA) containing 10% fetal calf serum (Hyclone, Waltham, MA), and
2mM L-glutamine (Gibco, Carlsbad, CA). Osteoclasts were differentiated from bone
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marrow as described(H. Zhao et al., 2008). Briefly, bone marrow was extracted from
mice and cultured in the presence of 10% CMG 14-12 supernatant(Takeshita, Kaji, &
Kudo, 2000), an M-CSF-containing cell supernatant, on day -4. After 4 days (day 0),
cells were lifted and replated on plastic or bovine bone fragments in alpha10 media
supplemented with 2% CMG and 100ng/mL recombinant RANKL. Bone-grown cells
were fixed in 4% paraformaldehyde 6 or 7 days after plating for immunofluorescence and
bone pit measurements. Plastic-grown cells were fixed on days 3, 4, and 5 in 4%
paraformaldehyde/PBS for osteoclastogenesis analysis or lysed on various days for
immunoblot analysis.

Retroviral DNA constructs mCherry-ATG5WT and mCherry-ATG5K130R were
generated in the laboratory of Dr. A. B. Gustafsson(Hamacher-Brady et al., 2007).
mStrawberry-ATG4BC74A was kindly provided by Dr. T. Yoshimori(Fujita, HayashiNishino et al., 2008). The eGFP construct was purchased from Clontech (Mountain
View, CA). All constructs were cloned into the pMXs-IRES-Puro retroviral vector (Cell
Biolabs, Inc., San Diego, CA). eGFP-IRES-Puro retrovirus and vector only retrovirus
were used as controls.
Proliferation and cell death ELISA assay BrdU proliferation assay was performed by
incubating cells for 18 hours in BrdU, followed by ELISA detection using the cell
proliferation Biotrak ELISA system (Amersham). Cell death was analyzed in
quadruplicate using cell death detection ELISAPLUS kit (Roche), which detects
cytoplasmic histone-associated DNA fragmentation.
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Retroviral transduction Retroviral transduction of bone marrow macrophages was
done as previously described, with slight modifications(H. Zhao et al., 2008). Briefly,
8ug of retroviral DNA was transfected into Plat-E cells using the Fugene HD transfection
reagent (Roche, Basel, Switzerland) the same day as bone marrow isolation. Plat-E
media was replaced 24 hours later and virus harvested 48 and 72 hours after for
transduction of plated bone marrow cells. To transduce the bone marrow cells, culture
media was replaced at 48 and 72 hours with alpha10 containing 25% Plat-E viral media,
10% CMG 14-12 supernatant, and 4ug/mL polybrene. At 96 hours the transduction
media was replaced with alpha10 with 10% CMG 14-12 supernatant and 2ug/mL
puromycin. Cells were allowed to grow for 3 days before being harvested and plated to
form osteoclasts. Control, untransduced cells were killed by the puromycin.

Immunofluorescence Osteoclasts grown on bone fragments were fixed in 4%
paraformaldehyde for 10 minutes and washed in PBS. Cells were permeabilized in 0.1%
Triton-X for 10 minutes at room temperature and blocked for 1 hour in PBS containing
0.2% BSA, 10% normal goat serum, and 10% normal rabbit serum. The following
antibodies and detection reagents were used: anti-cathepsin K (Millipore, Billerica, MA)
(1:500 dilution), mouse IgG1 isotype control (Southern Biotech, Birmingham, AL), antiGFP conjugated to Alexa 488 (Molecular Probes, Carlsbad, CA), polyclonal rabbit
antibody conjugated to Alexa 488 isotype control (anti-fluorescein, Molecular Probes,
Carlsbad, CA), anti-CD107a (eBioscience, San Diego, CA), rat anti-mouse IgG2a isotype
control (anti-mouse CD8a, BD Biosciences, San Jose, CA), phalloidin-Alexa 555 and
phalloidin-Alexa 488 (Molecular Probes, Carlsbad, CA), goat anti-rat-Alexa 488
(Molecular Probes, Carlsbad, CA), goat anti-mouse Cy5 (Jackson Immunoresearch, West
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Grove, PA), and donkey anti-mouse-Alexa 555 (Jackson Immunoresearch, West Grove,
PA). All antibodies were diluted in blocking buffer. Primary antibodies were applied
overnight. After washing in PBS, secondary antibodies were applied for 1 hour at room
temperature. Bones were then mounted in 30% glycerol or VECTASHIELD Mounting
Media with DAPI (Vector labs, Burlingame, CA) and imaged on a Nikon Eclipse
epifluorescent microscope (Nikon, Melville, NY), Olympus BX51 epifluorescent
microscope (Olympus, Center Valley, PA), or Axiovert 100M confocal microscope
(Zeiss, Thornwood, NY). Confocal images were analyzed using LSM 510 software
(Zeiss, Thornwood, NY).

For localization of GFP-LC3, cathepsin K, and LAMP1,

confocal microscopy was used to identify cells with complete actin rings. If the area
outlined by the actin ring was completely occupied by CatK in any z-plane containing the
actin ring, and CatK was not visualized outside the ring in those z-planes, the cell was
said to have positive CatK localization. The same procedure was followed for LAMP1
and GFP-LC3 localization. All data was collected by a blinded observer.
Immuno-electron microscopy.

For immunolocalization at the electron microscopy

level, osteoclasts on bone chips were fixed in 4% paraformaldehyde/0.05%
glutaraldehyde (Polysciences Inc., Warrington, PA) in 100mM PIPES/0.5mM MgCl2, pH
7.2 for 1 hr at 4°C. Samples were infiltrated overnight in the cryoprotectant 2.3M
sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl2 at 4°C. To permeabilize cells for
antibody labeling samples were plunge frozen in liquid nitrogen and subsequently thawed
in PBS at room temperature. This technique was confirmed to permeabilize the host cell
membrane and intracellular organelle membranes. Samples were probed with the rabbit
anti-GFP (Abcam 6556, 1:500) followed by FluoroNanogold anti-rabbit Fab (1:250)
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(Nanoprobes, Yaphank, NY) and silver enhancement (Nanoprobes HQ silver
enhancement kit).

Samples were washed in phosphate buffer and postfixed in 1%

osmium tetroxide (Polysciences Inc., Warrington, PA) for 1 hr. Samples were then
rinsed extensively in dH20 prior to en bloc staining with 1% aqueous uranyl acetate (Ted
Pella Inc., Redding, CA) for 1 hr. Following several rinses in dH20, samples were
dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella
Inc.). Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica
Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and
viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc.,
Peabody, MA). All prelabeling experiments were conducted in parallel with isotype
controls or omission of the primary antibody. These controls were consistently negative
at the concentration of Nanoprobes conjugated secondary antibodies used in these
studies.

Bone pit depth measurements Osteoclast-generated bone pits were stained by
removing the cells from bone fragments with a soft brush and incubating with 20ug/mL
FITC conjugated wheat germ agglutinin (Sigma, St. Louis, MO) for 30 minutes at room
temperature. After washing the bones, pits were imaged by confocal microscopy. The
pit depth was measured from the surface of the bone down to the deepest point in the pit.
All data was collected by a blinded observer.

Nuclei Counts

Osteoclasts were grown on bone for 6 days and fixed and

permeabilized as described above.

Cells were stained with Alexa 555-conjugated

phalloidin and mounted with VECTASHIELD Mounting Media with DAPI to visualize
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actin rings and nuclei. Nuclei per cell were quantified counting any cell with at least
three nuclei.
Osteoclastogenesis Osteoclasts were grown on plastic in 48-well plates for 3-5 days and
fixed with 4% PFA, as described above. TRAP staining on fixed cells was performed
using a commercially available kit according to the manufacturer's instructions (Sigma,
St. Louis, MO). All TRAP+ cells with at least three nuclei were counted, with 2-3 wells
counted per genotype.

Immunoblots Cells were lysed in RIPA buffer + protease inhibitors for 10 minutes on
ice, the lysates were clarified, 5x Laemmli sample buffer added, and the samples boiled.
Immunoblotting was performed using antibodies against ATG5 (Nanotools, Teningen
Germany) (1:200 dilution), LC3 (Cosmo Bio Co, LTD, Tokyo, Japan) (1:500 dilution),
ATG7 (Sigma-Aldrich, St. Louis MO) (1:2,000 dilution), β-actin (Sigma-Aldrich, St.
Louis MO) (1:40,000 dilution), p62 (Progen Biotechnik, Heidelberg, Germany) (1:1,000
dilution), Atg4B (MBL, Woburn, MA) (1:1,000 dilution), c-Src (monoclonal antibody
directed against c-Src was a gift from A. Shaw) (final concentration: 2ug/mL), β3
integrin (Cell Signaling Technology) and cathepsin K (Millipore, Billerica, MA) (1:500
dilution).

Quantification of immunoblot results was performed using a Storm 840

phosphorimager (Molecular Dynamics, Piscataway, NJ) and ImageQuant software (GE,
Piscataway, NJ).

Microcomputed tomography and ovariectomy Trabecular volume in the distal
femoral metaphysis (right leg) was measured using in vivo microcomputed tomography
(vivaCT 40, Scanco Medical, Brüttisellen, Switzerland) while the mice were anesthetized
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with isofluorane. A threshold linear attenuation coefficient of 1.2 cm−1 was used to
differentiate bone from non-bone. A threshold of 120 was used for evaluation of all
scans. 30 slices were analyzed, starting with the first slice in which condyles and primary
spongiosa were no longer visible. Trabecular volume was measured one day before
ovariectomy or sham operation (basal bone volume) and 28 days after surgery (post-ovx).
For ovariectomies, mice were anesthetized with ketamine/xylene delivered by
intraperitoneal injection, and ovaries were removed through two small dorsal incisions.
Sham operated mice were anesthetized and opened equivalently, but ovaries were not
removed.
Electron microscopy Proximal tibiae of 2-month-old mice were fixed with 4% PFA
overnight and decalcified in 14% EDTA for 7 days. The samples were then postfixed in
2% OsO4/3% K-ferrocyanide for 2 hr, dehydrated in ethanol, and embedded in Epon LX
112. Ultrathin sections were stained briefly with lead citrate and examined using a JEOL
100SX transmission electron microscope.
Transmission electron microscopy. For immunolocalization at the electron microscopy
level, osteoclasts on bone chips were fixed in 4% paraformaldehyde/0.05%
glutaraldehyde (Polysciences Inc., Warrington, PA) in 100mM PIPES/0.5mM MgCl2, pH
7.2 for 1 hr at 4°C. Samples were infiltrated overnight in the cryoprotectant 2.3M
sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl2 at 4°C. To permeabilize cells for
antibody labeling samples were plunge frozen in liquid nitrogen and subsequently thawed
in PBS at room temperature. This technique was confirmed to permeabilize the host cell
membrane and intracellular organelle membranes. Samples were probed with the rabbit
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anti-GFP (Abcam 6556, 1:500) followed by FluoroNanogold anti-rabbit Fab (1:250)
(Nanoprobes, Yaphank, NY) and silver enhancement (Nanoprobes HQ silver
enhancement kit).

Samples were washed in phosphate buffer and postfixed in 1%

osmium tetroxide (Polysciences Inc., Warrington, PA) for 1 hr. Samples were then
rinsed extensively in dH20 prior to en bloc staining with 1% aqueous uranyl acetate (Ted
Pella Inc., Redding, CA) for 1 hr. Following several rinses in dH20, samples were
dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella
Inc.). Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica
Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and
viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc.,
Peabody, MA). All prelabeling experiments were conducted in parallel with isotype
controls or omission of the primary antibody. These controls were consistently negative
at the concentration of Nanoprobes conjugated secondary antibodies used in these
studies.
Transmission electron microscopy (Cathepsin K)

For the immunolocalization of

cathepsin K, osteoclasts grown on a plastic substrate were fixed in 4% w/v
paraformaldehyde in 0.1 M phosphate buffer (pH=7.4) (Slot and Geuze, 2007).
Preparation of the samples, cryosectioning and immunogold labeling was performed as
described (Slot and Geuze, 2007). Cathepsin K was detected with a mouse monoclonal
antibody from Millipore (Billerica, MA) (Van Meel et al., 2011). Subsequently, a rabbit
polyclonal antibody against mouse immunoglobulins was used as a bridging step between
the cathepsin K antibody and protein A-gold (Dako, Heverlee, Belgium).

72

Serum Ctx measurements

Blood was collected by cheek puncture after 6 hours

starvation. Plasma was obtained using plasma separator tubes with lithium heparin
(Becton Dickinson). Serum CTx-I, a specific marker of osteoclastic bone resorption, was
measured using a RatLaps ELISA kit from Nordic Bioscience Diagnostics A/S.
Actin ring formation Osteoclasts on bone were incubated in cold alpha10 media for 30
minutes to disrupt actin rings, followed by warm alpha10 with 10% FBS, RANKL, and
M-CSF.

Cells were fixed at the indicated times, and actin rings were stained and

counted.
Statistics All data was analyzed with Prism software (Graphpad, San Diego, CA), using
two-tailed unpaired Student’s t tests, unless otherwise indicated. Error bars represent
standard deviation.
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Chapter 3: IL-17 is Critical in the
Pathogenesis of Osteoporosis
Abstract
Although not traditionally thought of as an inflammatory disease, estrogen
deficiency osteoporosis is partially mediated by T cells, at least in mice (Weitzmann &
Pacifici, 2007). Th17 cells, which secrete IL-17, are implicated in a number of
inflammatory and autoimmune conditions, including arthritis-mediated bone destruction.
We find IL-17 critical in the pathogenesis of bone loss due to estrogen deficiency. IL-17
receptor deficient mice are protected from bone loss after ovariectomy, as are mice
treated with a neutralizing IL-17 antibody. The effect of IL-17 on osteoclasts is indirect,
via osteoblastic upregulation of RANKL. The SEFIR domain of IL-17R is critical for
osteoblast-mediated osteoclast formation and RANKL production. The adaptor protein
Act1 is required for osteoblast-mediated osteoclast formation in response to IL-17, and
Act1 deficient mice are also protected from bone loss induced by estrogen deficiency.
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Introduction
Autoimmune and inflammatory conditions have long been known to cause bone
loss, suggesting a connection between the T-cell and the bone-resorbing osteoclast.
Osteoclast formation requires two cytokines: Receptor Activator of NFKB Ligand
(RANKL) and Macrophage Colony Stimulating Factor (M-CSF), produced primarily by
osteoblasts and bone marrow stromal cells (Lacey et al., 1998; Yasuda et al., 1998).
Though RANKL and M-CSF are essential, additional cytokines can modulate osteoclast
formation. The best studied are TNFα and IL-1, which upregulate RANKL production
on osteoblasts (Cenci et al., 2000; Hofbauer et al., 1999; Lam et al., 2000; Sherman,
Weber, Datta, & Kufe, 1990; Wei, Kitaura, Zhou, Ross, & Teitelbaum, 2005).
CD4+ T helper cells are heterogeneous and can be characterized by the cytokine
profiles they produce. CD4+ T helper type 1 (Th1) cells produce interferon (IFN)-γ, and
regulate influx of macrophages. CD4+ Th2 cells produce mainly IL-4 and induce
immunoglobulin (Ig)E production, recruit eosinophils to inflammatory sites, and help
clear parasites. Treg cells develop to inhibit over-activation of the T-cell response, to
save normal tissue from unnecessary destruction. More recently, a population of CD4+ T
cells was identified that preferentially produces IL-17A and IL-17F, as well as IL-22,
termed Th17 cells (Bettelli et al., 2006; Harrington et al., 2005; Mangan et al., 2006; Park
et al., 2005). Th17 cells are thought to arise when naïve CD4+ are stimulated with TGFβ, which induces both RORγt and Foxp3 transcription factors. These cells now have dual
potential to differentiate into either the Th17 or Treg cells depending on the cytokine
environment. In the presence of proinflammatory cytokines such as IL-6, IL-21, or IL-23,
and low concentrations of TGF-β, RORγt expression is further upregulated, whereas
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Foxp3 is inhibited, and Th17 cells develop. In contrast, in the absence of
proinflammatory cytokines, high concentrations of TGF-β along with retinoic acid and
IL-2 are optimal for Foxp3 expression and promote Treg cell differentiation (Zhou et al.,
2008). RORγt is required for Th17 cell differentiation and is both necessary and
sufficient for induction of IL-17 and other genes characteristic of Th17 cells, but RORα
also plays a role (Ivanov et al., 2006; Yang et al., 2008; Zhang, Meng, & Strober, 2008).
Other transcription factors are necessary for Th17 development and mainly work by
modifying RORγt expression or function, including interferon regulatory factor 4 (IRF4),
the aryl hydrocarbon receptor (AHR), runt-related transcription factor 1 (RUNX1), Stat3,
and basic leucine zipper transcription factor, ATF-like (BATF) (Brustle et al., 2007;
Chen et al., 2006; Quintana et al., 2008; Schraml et al., 2009; Veldhoen et al., 2008;
Zhang et al., 2008). Th17 cells can be induced from naïve T-cells using only IL-6 and
TGF-β (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen, Hocking, Atkins, Locksley,
& Stockinger, 2006), while TNF-α, IL-23, and IL-1β amplify their development (Sutton,
Brereton, Keogh, Mills, & Lavelle, 2006), and IFNγ and IL-4 are inhibitory (Harrington
et al., 2005).
IL-17A is the founding member of the IL-17 family, but five other members have
been described. Th17 cells produce IL-17A and IL-17F, which are most similar in
homology and function (Kolls & Lindén, 2004). IL-17 forms a dimer, with A/A being the
most potent, followed by A/F and F/F (Liang et al., 2007). Here we will refer to IL-17A
simply as IL-17. IL-17 is an important mediator of inflammation, recruiting neutrophils
and inducing TNF-α, IL-1β, IL-6, IL-8, and other inflammatory cytokines by
macrophages, fibroblasts, and other cells. IL-17 activates a number of kinase cascades in
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many cell types, including canonical NFkB, Akt, JNK, ERK 1/2, and p38 (Kim et al.,
2007; Liu et al., 2009; Shalom-Barak, Quach, & Lotz, 1998).
The IL-17 receptor (IL-17R, or IL-17AR) binds both IL-17 and IL-17F (Shen &
Gaffen, 2008), and contains a cytoplasmic SEFIR domain (similar expression to
fibroblast growth factor genes, IL-17 receptors and Toll–IL-1R) (Novatchkova,
Leibbrandt, Werzowa, Neubuser, & Eisenhaber, 2003). This domain is required for the
activation of Mitogen-Activated Protein Kinases (MAPKs) and the transcription factors
NF-κB, C/EBPβ, and C/EBPδ (Maitra et al., 2007). The SEFIR domain is similar to the
Toll-interleukin 1 receptor (TIR) domain. Both SEFIR and TIR are implicated in
homotypic dimerization (Novatchkova et al., 2003), and both are required for activation
of NFkB in fibroblasts. A single point mutation within the SEFIR (V553H) is sufficient
to eliminate IL-17-dependent NFkB activation (Maitra et al.). Deletion of the SEFIR
motif also prevents ERK activation.
Activated IL-17R interacts with the adaptor protein Act1 (transcription factor NFkB activator 1). Act1 was identified as an activator of NFkB, p38, and JNK (Leonardi,
Chariot, Claudio, Cunningham, & Siebenlist, 2000; Li et al., 2000). Fibroblasts lacking
Act1 fail to activate NFkB when IL-17 stimulated, but ERK phosphorylation after 24
hours of stimulation is unaffected (Qian et al., 2007). Act1 contains two TRAF binding
sites, as well as a helix-loop-helix and a coiled-coil domain (Li et al., 2000). Like the IL17R, Act1 has a SEFIR domain, which mediates its interaction with IL-17R upon
activation. After binding IL-17R, Act1 recruits transforming growth factor β–activated
kinase 1 (TAK1) and TRAF6 to mediate downstream signaling (Qian et al., 2007;
Schwandner, Yamaguchi, & Cao, 2000). Act1 contains a Ubox-like domain, which can
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act as an E3 ubiquitin ligase to ubiquitinate TRAF6. Ubiquitination is K63-dependentent,
and is critical for IL-17 mediated NFkB, JNK, and ERK activation (Liu et al., 2009).
Although previous data suggests TRAF6 ubiquitinates itself, TRAF6 is not ubiquitinated
in IL-17-stimulated Act1 KO MEFs or Act1 KO MEFs reconstituted with Ubox-mutant
Act1, suggesting Act1 may be the ubiquitin ligase necessary for TRAF6 ubiquitination
(Liu et al., 2009; Petroski et al., 2007). TRAF6 KO cells reconstituted with RING
domain mutant TRAF6 also have impaired activation of NFkB in response to IL-17,
suggesting Act1 E3 ligase may be important for TRAF6 ubiquitination, but TRAF6 E3
ligase activity is still necessary for downstream signaling (Liu et al., 2009).
The IL-17R is not the only pathway that utilizes Act1. Act1 also regulates
signaling from the TNF receptor family members BAFFR, which is required for B-cell
maturation, and CD40, which mediates T-cell dependent B-cell activation (Kanamori,
Kai, Hayashizaki, & Suzuki, 2002; Qian, Zhao, Jiang, & Li, 2002). Act1 KO mice have
more peripheral B cells, leading to lymphadenopathy, splenomegaly,
hypergammaglobulinemia, and the production of auto-antibodies (Qian et al., 2004).
Stimulation of splenic B cells from Act1 KO mice with CD40 and BAFF (B cell–
activating factor belonging to the TNF family) results in enhanced cellular differentiation
and survival. These effects are associated with enhanced IκB phosphorylation, processing
of NF-κB2, and activation of JNK, ERK, and p38, suggesting Act1 negatively regulates
these signaling events in response to BAFF ligand and CD40 antibody, in contrast to its
activating role in response to IL-17 (Qian et al., 2004). However, cellular specificity may
exist, since epithelial cells utilize Act1 as a positive mediator of NFkB activation in
response to CD40L (Qian et al., 2002).
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While NFkB signaling in osteoclasts is well studied, only recently was the role of
NFkB in the osteoblast established. Genetic NFkB inhibition in mature osteoblasts
causes increased bone formation in vivo and in vitro, resulting in osteopetrosis (Chang et
al., 2009). The mechanism is thought to involve prolonged JNK phosphorylation leading
to Fra-1 (encoded by Fosl-1, an AP-1 type transcription factor) expression. Knocking
down Fra-1 inhibited bone mineralization and reduced levels of the bone matrix genes
Ocn, Ibsp and Col1a2 (Chang et al., 2009). Previously it was found that osteoblastspecific expression of transgenic Fra-1 leads to osteosclerosis due to enhanced
osteoblastogenesis and bone formation (Jochum et al., 2000), while mice with osteoblastspecific deletion of Fra-1 are osteopenic with a defect in osteoblast differentiation, but no
effect on the number of osteoblasts (Eferl et al., 2004). Although the primary ligand was
not identified for the osteoblast, these data suggest NFkB signaling in mature osteoblasts
inhibits bone formation, while in osteoclasts the same signaling causes increased bone
resorption.
Rheumatoid arthritis (RA) is a classic example of inflammatory disease causing
bone and joint destruction. It was originally thought RA was predominantly Th1
mediated (Kotake et al., 2001; Yamada et al., 2008). However, the primary Th1
cytokine, IFNγ, was found to suppress osteoclastogenesis by inducing TRAF-6
degradation (Huang, O'Keefe, & Schwarz, 2003; Pang, Martinez, Jacobs, Balkan, &
Troen, 2005; Takayanagi et al., 2000), and other Th1 cytokines including GM-CSF, IL12, and IL-18 were shown to inhibit bone resorption in vitro (Amcheslavsky & BarShavit, 2006; Nakashima & Takayanagi, 2008; Tunyogi-Csapo et al., 2008). In vivo,
IFNγ is protective against arthritis, and IFNγ deficient mice are more susceptible to
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autoimmune arthritis manifestations (Chu, Song, Mayton, Wu, & Wooley, 2003; Irmler,
Gajda, & Brauer, 2007). The primary culprit is now thought to be the Th17 cell, for its
ability to produce or induce the bone destructive cytokines TNFα, IL-1, IL-6 and IL-17.
Th17 cells enhance osteoclastogenesis in coculture much more efficiently than Th1 or
Th2 cells (Sato et al., 2006). The pro-osteoclastic effect of IL-17 is thought to be indirect,
by stimulation of osteoblasts to express RANKL (Page & Miossec, 2005; Sato et al.,
2006), but IL-17 was also found to directly enhance osteoclastogenesis in a monoculture
of human macrophages (Yago et al., 2009). In another study, IL-17 actually inhibited
osteoclastogenesis from RAW264.7 macrophages (Kitami et al.). TNFα, produced by
both Th17 and Th1 cells, has a synergistic effect with IL-17 on many targets (Miossec,
2003).
Osteoporosis in humans most commonly occurs post-menopause, during which
estrogen levels decrease and osteoclast numbers increase. The mechanism by which low
estrogen leads to bone loss is complex, but is thought to occur through osteoblastmediated osteoclast formation and activation. Although osteoporisis is not associated
with inflammation, T-cells and TNFα are proposed to play a critical role. Nude mice
lacking T-cells are protected from bone loss induced by ovariectomy, while nude mice
reconstituted with T-cells are not (Cenci et al., 2000; Roggia et al., 2001); (Felix,
Cecchini, & Fleisch, 1990; Kong et al., 1999; Roggia et al., 2001). TNF-/- mice are
protected from ovariectomy-induced osteoporisis (Roggia et al., 2001), as are transgenic
mice overexpressing a soluble TNF-receptor (Ammann et al., 1997), and mice treated
with inhibitory TNF-binding protein (Kimble, Bain, & Pacifici, 1997). The source of the
TNF in this circumstance is T-cells, not BMMs. The type of T-cell involved has not been
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studied, but similar to the case of RA-mediated bone loss, Th1 cells are unlikely culprits
because of the bone-protective function of IFNγ. Recently, IL-17R-/- mice were reported
to have more fat and more leptin, as well as more whole-body bone loss after
ovariectomy as measured by Dual energy X-ray absorptiometry (DEXA) (Goswami,
Hernandez-Santos, Zuniga, & Gaffen, 2009). However, fat distribution independently
affects bone density readings by DEXA (Formica, Loro, Gilsanz, & Seeman, 1995;
Hangartner & Johnston, 1990; Tothill, Hannan, Cowen, & Freeman, 1997; Tothill,
Laskey, Orphanidou, & van Wijk, 1999; Wren, Kim, Janicka, Sanchez, & Gilsanz, 2007),
making the technique less appropriate than micro-CT in many circumstances. Given the
role of IL-17 in inflammatory bone loss, the importance of TNFα in osteoprosis, and the
synergistic effects of TNFα and IL-17 on target tissues (Miossec, 2003), we studied the
effect of IL-17 signaling on osteoclastogenesis and osteoporosis.
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Results
IL-17R Deficiency or Treatment with IL-17 Blocking Antibody Protects Mice From
Bone Loss Induced by Estrogen Deficiency
To test whether IL-17 signaling is important in the pathogenesis of osteoporosis, we
mimicked the most common human form of osteoporosis, that of estrogen deficiency, by
removing ovaries (ovx) in mice. Micro-CT, a sensitive and specific measure of bone
volume, was used to assess trabecular bone. While WT mice exhibited significant bone
loss after ovx, minor, non-significant changes were observed in IL-17R KO animals
(Figure 3.1). To further establish the role of IL-17 in this process, we selected an IL-17
blocking antibody for its ability to inhibit osteoclastogenesis in a coculture of BMMs
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with osteoblasts and IL-17 (Figure 3.2). Both two weeks (Figure 3.3) and four weeks
(Figure 3.4) post-ovx, injection of the blocking antibody protected animals from bone
loss, while injection of an isotype control antibody had no effect. To test another
experimental system, we ovariectomized mice lacking BATF, which is reported to be
essential for Th17 cell differentiation (Schraml et al., 2009). To our surprise, BATF KO
mice were not protected from bone loss (Figure 3.5). Thus, Th17-independent sources of
IL-17, perhaps derived from bone marrow resident cells, mediate bone loss induced by
ovariectomy. These data suggest IL-17 is important in the pathogenesis of osteoporosis,
and suggest pharmacologic inhibition with either antibody against IL-17 may ameliorate
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osteoporosis induced by estrogen loss.
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IL-17 Stimulates Osteoclastogenesis Indirectly Through the Osteoblast
Since different groups report IL-17 having both a direct and indirect effect on
osteoclast development, we first cultured BMMs with varying concentrations of M-CSF,
RANKL, and IL-17, and observed no differences in osteoclast formation (Figure 3.6). To
test the function of IL-17 signaling in the osteoblast, we first determined the IL-17
receptor is expressed in osteoblasts, and its expression is unaffected by TNFα or IL-17
stimulation (Figure 3.7). Next we cultured BMMs in combination with primary
osteoblasts and varying IL-17 concentrations. IL-17 potently induced osteoclast
formation, even at low levels (Figure 3.8). RANKL mRNA expression in the osteoblast is
induced by IL-17 (Figure 3.9), explaining the cytokine’s pro-osteoclastogenic effect. IL17 does not affect osteoblast proliferation (Figure 3.10). This suggests IL-17 is unable to
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directly induce osteoclastogenesis, but instead acts through the osteoblast.
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The IL-17R SEFIR Domain is Necessary for Osteoblast-induced Osteoclast
Formation
To determine the domains of IL-17R necessary for osteoclast formation, we
retrovirally transduced primary IL-17R KO osteoblasts with WT or mutant IL-17R.
Coculture with WT BMMs and low or high levels of IL-17 demonstrated efficient
osteoclastogenesis in cultures containing IL-71R KO osteoblasts reconstituted with WT
IL-17R, a mutant lacking the distal cytoplasmic domain (d665), or a point mutant in a
hypothetical disulfide bond-forming residue (R549A) (Figure 3.11, Figure 3.12).
However, osteoblasts reconstituted with IL-17 receptor lacking the SEFIR domain
(dSEFIR) were unable to induce osteoclastogenesis in response to IL-17 (Figure 3.11).
Osteoblasts containing WT, d665, or R549A mutant IL-17 receptor displayed efficient
RANKL mRNA induction in response to IL-17, while dSEFIR reconstituted osteoblasts
exhibited poor IL-17-induced RANKL expression (Figure 3.13, Figure 3.14). These
results suggest the SEFIR domain is critical for osteoclast induction by IL-17.
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Act1 is Critical for IL-17 Dependent Osteoclast Formation
Act1 is downstream of not only IL-17, but also the TNFR superfamily members
CD40 and BAFFR (Li, 2008), and can act as an E3 ubiquitin ligase for TRAF6 (Liu et
al., 2009). RANK, the TNFR family member in the osteoclast, requires TRAF6 for
signaling (Lomaga et al., 1999; Naito et al., 1999), so we tested whether Act1 deficiency
affects osteoclast differentiation in response to RANKL. Osteoclast differentiation is
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equivalent in Act1 WT and KO osteoclasts, suggesting Act1 is not a downstream
mediator of RANK signaling (Figure 3.15). Additionally, Act1 deficiency does not
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affect osteoblast differentiation (Figure 3.16) or proliferation (Figure 3.17). Coculture of
BMMs with WT or KO Act1 osteoblasts and IL-17 revealed enhanced osteoclast
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formation only in the presence of Act1 (Figure 3.18).
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Figure 3.14: qPCR of RANKL Expression of IL-17R Mutants
Stimulated with IL-17
Wild-type and IL-17R knockout osteoblasts were transduced with empty
vector (EV) or various IL-17R mutants and stimulated with 10 ng/ml
IL-17. RANKL expression was measured by qPCR.
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Figure 3.15: Act1 does not Mediate Osteoclast Differentiation
Act1 WT and KO bone marrow macrophages were grown with RANKL and
MCSF for the indicated number of days, then fixed and trap stained.
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Figure 3.16: Osteoblasts Differentiate Normally in the Absence of Act1
Primary osteoblasts were isolated from Act1 WT and KO calvaria,
differentiated for 20 days, and stained for alkaline phosphosphatase.
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Figure 3.17: Act1 Deficiency Does not Affect Osteoblast Proliferation
Act1 WT and KO osteoblasts were cultured with BrdU for 16 hours, after
which BrdU incorporation was determined by absorptiometry.
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Figure 3.18: Act1 is Necessary for IL-17-Induced Osteoclast Formation in Coculture
Act1 KO osteoblasts were transduced with empty vector or WT Act1, and Act1 KO
osteoblasts were transduced with empty vector. These osteoblasts were
cocultured with bone marrow macrophages in the presence of Vitamin D and
the indicated amount of IL-17. Osteoblasts were lifted and osteoclasts were
trap stained.

Act1 Expression, but not IL-17RA, is Regulated by Estrogen in vitro and in vivo
These data raise the possibility that estrogen exerts its bone-sparing effects, at least in
part, by suppressed expression of Il-17 effectors, such as Act1. To determine if such is
the case, we first established that estrogen supplementation does not significantly affect
expression of IL-17RA (Figure 3.19) and Act1 (Figure 3.20) mRNA by WT osteoblasts.
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We then exposed osteoblasts to estrogen for 5 days followed by 5 days in the absence of
the steroid. As control, the osteoblasts were maintained in the presence of the steroid for
the entire 10 days of culture. Estrogen withdrawal does not affect IL-17RA mRNA
(Figure 3.21) expression but increases that of Act1 (Figure 3.22). To confirm the in vivo
significance, mice were subjected to Ovx or sham procedures, and two weeks later
femora were removed, pulverized (bone marrow was first removed by centrifugation),
and extracted of mRNA. Act1 levels significantly increase post-ovx compared to sham,
while IL-17R do not significantly change (Figure 3.23, Figure 3.24).
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Figure 3.19: Estrogen Does not Significanlty Affect IL-17R Expression
Wt osteoblasts were exposed to estrogen (10nm) with time. IL-17RA mRNA
was measured by qPCR.
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Figure 3.20: Estrogen Does not Significanlty Affect Actt1 Expression
Wt osteoblasts were exposed to estrogen (10nm) with time. Act1 mRNA
was measured by qPCR.
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Figure 3.21: Estrogen Deprivation Does not Significanlty Affect IL-17R
Expression
Wt osteoblasts were exposed to estrogen (10nm) for five day followed by
five days of continued estrogen (E2) or estrogen deprivation (E2 deprivation).
IL-17R expression was measured by qPCR.
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Figure 3.22: Estrogen Deprivation Significanlty Increases Act1
Expression
Wt osteoblasts were exposed to estrogen (10nm) for five day followed by
five days of continued estrogen (E2) or estrogen deprivation (E2 deprivation).
Act1 expression was measured by qPCR.
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Figure 3.23: Act1 Expression Increases in the Bone following
Ovariectomy
Wt mice were subjected to OVX or sham procedures, and bone devoid of
marrow was harvest for mRNA. Act1 expression was measured by qPCR.
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Figure 3.24: IL-17R Expression Does Not Significantly Change in the
Bone following Ovariectomy
WT mice were subjected to OVX or sham procedures, and bone devoid of
marrow was harvest for mRNA. IL-17R expression was measured by qPCR.

Act1 Deficiency Protects Mice from Estrogen Loss Osteoporosis
Micro-CT analysis of trabecular bone established that baseline bone volume is
unaffected by global loss of Act1 (Figure 3.25). However, after ovariectomy, Act1 KO
mice maintain higher bone mass (Figure 3.25), which is consistent with an essential
downstream role of Act1 in IL-17-induced bone pathology.
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Figure 3.25: Act1-deficient Mice are Protected from OVX-induced Bone
Loss
Eight-week old mice were subjected to ovariectomy or sham procedure,
and bone volume/total volume (BV/TV) of distal femora was measured by
micro-CT after four weeks. n = 6 mice per goup.
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Discussion
IL-17 is an inflammatory cytokine associated with a variety of disorders, including
rheumatoid arthritis, where it promotes osteoclast formation and bone resorption.
Osteoporosis resulting from estrogen deficiency is dependent on T cells, specifically the
TNF produced by T cells. We find bone loss due to estrogen deficiency is also dependent
on IL-17. IL-17R KO mice exhibit minimal changes in trabecular bone after
ovariectomy, as do WT mice treated with IL-17 blocking antibody. The downstream IL17R signaling protein Act1 is critical in this process, as Act1 KO mice are protected from
the bone loss of ovariectomy. IL-17 promotes bone loss by stimulating RANKL
production in the osteoblast, a process that requires the SEFIR domain of the IL-17
receptor. Similarly, Act1 is essential in the osteoblast, but not osteoclast, for IL-17mediated bone resorption. Unexpectedly, a previous report found IL-17R deficient mice
actually lose more whole-body bone density after ovariectomy than do WT controls
(Goswami et al., 2009). As mentioned earlier, these differences may be due age
differences in the mice, or to the use of DEXA versus micro-CT, since DEXA
measurements of bone density are influenced by fat distribution (Formica et al., 1995;
Hangartner & Johnston, 1990; Tothill et al., 1997; Tothill et al., 1999; Wren et al., 2007),
which is potentially affected by IL-17 (Goswami et al., 2009; Shin, Shin, & Noh, 2009;
Sumarac-Dumanovic et al., 2009).
The necessity of both IL-17 and TNF in estrogen deficiency bone loss may be
explained by the effect of IL-17 and TNF on target tissues alone or in combination. IL-17
and TNFα have a synergistic effect on most cells, including the osteoblast (Chabaud et
al., 2000; Chabaud, Lubberts, Joosten, van Den Berg, & Miossec, 2001; Chabaud, Page,
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& Miossec, 2001; Hata et al., 2002; Jones & Chan, 2002; Katz, Nadiv, & Beer, 2001;
Koshy et al., 2002; Laan et al., 1999; LeGrand et al., 2001; Martel-Pelletier, Mineau,
Jovanovic, Di Battista, & Pelletier, 1999; Miossec, 2003). Thus, similar to reports that
blockade of IL-17 can prevent TNFα-induced arthritis (Lubberts, Koenders, & van den
Berg, 2005), inhibiting the IL-17 pathway may effectively diminish the effect of TNFα in
estrogen-loss osteoporosis.
It is interesting that mice lacking the IL17R are protected from osteoporosis, but
mice lacking BATF, which is required for Th17 cell development, are not. It is possible
cells besides Th17 cells are producing IL-17 in the bone microenvironment or elsewhere,
providing sufficient levels of the cytokine for bone loss. IL-17 is known to be produced
by mast cells, γδ T cells (CD4– and CD8– T cells), a memory subset of cytotoxic T cells,
invariant natural killer T cells, macrophages, and neutrophils (Ferretti, Bonneau, Dubois,
Jones, & Trifilieff, 2003; Happel et al., 2003; Hueber et al., ; Ivanov et al., 2007; Kolls &
Linden, 2004; Lockhart, Green, & Flynn, 2006; Maek, Buranapraditkun,
Klaewsongkram, & Ruxrungtham, 2007; Michel et al., 2007; Shin, Benbernou, Esnault,
& Guenounou, 1999; Song et al., 2008). One study found the major source of IL-17 in
the arthritic joint is the mast cell (Hueber et al.). It is also possible that BATF deficiency
does not completely abolish the Th17 population in our experimental osteoporosis model.
IL-1 and lipopolysaccharide (LPS) are osteoclastogenic and their receptors share a
common Toll/IL-1R (TIR) sequence. IL-17 receptors contain an intracellular SEFIR
domain, homologous to the TIR motif, a docking site for adaptor proteins (Maitra et al.,
2007). A distal component of the SEFIR domain, known as TILL, is unique to IL-17RA
and in other circumstances, its mutation disables the receptor’s activity. The TILL-
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residing amino acid, R549, generates a key salt bridge in the homologous TIR domain.
Recently, Onishi et al established that signals emanating from IL-17RA require a large
extension distal to the TILL component of the SEFIR domain (Onishi et al). While
deletion of the distal SEFIR and its entire TILL sequence, in IL-17RA, forestalls IL-17stimulated osteoclastogenesis and RANKL expression by osteoblasts, the process occurs
independently of R549 and its putative salt bridge formation. This observation is in
keeping with the fact that IL-17RAR549A does not impair IL-17/TNF- induced signaling in
transformed cells (Maitra et al., 2007). Thus, while the LPS, IL-1 and IL-17 are each
osteoclastogenic, homologous components of their receptors may function differently.
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Methods
Mice All animals were housed in the animal care unit of the Washington University
School of Medicine and were maintained according to guidelines of the Association for
Assessment and Accreditation of Laboratory Animal Care. All animal experimentation
was approved by the Animal Studies Committee of the Washington University School of
Medicine.
Histological analysis Tibias were harvested, cleaned of soft tissue, and fixed in 10%
buffered formalin overnight. For non-decalcified sections, tibias were dehydrated by
incubation in an ethanol gradient (20%, 30%, 50%, 70% ETOH, for 30 minutes each).
Bones stored in 70% ETOH were then embedded in methylmethacrylate and cut into 5µm
longitudinal sections. Non-decalcified sections were left unstained. For decalcified
sections, following fixation, tibias were rinsed in water then incubated in 14% EDTA (pH
7.2) for 7 days with solution changes every 3.5 days. Following decalcification, tibias
were rinsed in water then incubated in the ETOH gradient described above. Bones stored
in 70% ETOH were then embedded in paraffin, cut into 4µm longitudinal sections, and
stained with TRAP or hematoxylin and eosin for visualization of osteoclasts or
osteoblasts, and measurements were made using BioQuant software (Bioquant;
Nashville, TN).
Bone formation assay (calcein double labeling) Mice were injected with 7.5mg/kg
calcein (Sigma-Aldrich; St. Louis, MO). Five days later mice were injected again, and
tibias were harvested after an additional 2 days for histologic analysis.

Dynamic

assessment of trabecular bone formation was determined on non-decalcified sections
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using BioQuant software (Bioquant; Nashville, TN). This software provided measures of
bone surface, percent single- (sLS/BS) and double-labeled (dLS/BS) bone surface,
mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate
(BFR/BS). Trabecular bone measurements were taken from a region encompassing a
500µm-long field, across the width of the bone (located 100µm below the growth plate).
For each animal, 2 serial sections were analyzed and the measurements averaged.
Pictures were obtained using an Olympus 1X51 fluorescent microscope fitted with
Olympus DP70 camera (Olympus; Center Valley, PA).
Cell culture Osteoclasts were grown in alpha10 media, containing alpha-MEM (Sigma
Aldrich, St. Louis, MO), 10% fetal calf serum (Hyclone, Waltham, MA), 100U/mL
penicillin and 100ug/mL streptomycin. Plat-E retrovirus packaging cells were purchased
from Cell Biolabs, Inc. (San Diego, CA) and maintained in DMEM media (Cellgro,
Manassas, VA) containing 10% fetal calf serum (Hyclone, Waltham, MA), and 2mM Lglutamine (Gibco, Carlsbad, CA). Osteoclasts were differentiated from bone marrow as
described(Zhao et al., 2008). Briefly, bone marrow was extracted from mice and cultured
in the presence of 10% CMG 14-12 supernatant(Takeshita, Kaji, & Kudo, 2000), a MCSF-containing cell supernatant. After 4 days, cells were lifted and replated on plastic or
bovine bone fragments in alpha10 media supplemented with 2% CMG and 100ng/mL
recombinant RANKL. Bone-grown cells were fixed in 4% paraformaldehyde 6 or 7 days
after plating.

Plastic-grown cells were fixed on days 3, 4, and 5 in 4%

paraformaldehyde/PBS for osteoclastogenesis analysis or lysed on various days for
immunoblot analysis.
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RT-PCR

RNA was isolated using RNeasy kits (Qiagen); RLT lysis buffer was

supplemented with β-mercaptoethanol (1%). Purified RNA was treated with DNase I
(Invitrogen; Carlsbad, CA) prior to reverse transcription (RT). RT was performed using
SuperScript III (Invitrogen). A negative control using RNA not subjected to reverse
transcription was included in each assay. Quantitative PCR (qPCR) was performed using
Applied Biosystems’s (Foster City, CA) Power SYBR green master mix and gene
specific primers. The qPCR reaction was run on Applied Biosystem’s ABI Prism 7000.
Transcript levels were normalized to cyclophilin.
Quantitative RT-PCR For ex-vivo RNA analysis, bone marrow was removed from
femora by centrifugation.

The remaining bone was frozen in liquid nitrogen and

pulverized using a Braun Mikrodismembrator (Sartorius BBI Systems Inc., Bethlehem,
PA) in an RNAase-free environment. RNA was extracted using Trizol (Invitrogen)
following manufacturer’s protocol. Quantitative PCR was performed using TaqMan
probes to IL-17RA (Invitrogen, Mm00434214) Act1 (Invitrogen, Mm00506094),
RANKL (Invitrogen, Cat #4331182) and as a control, Cyclophillin (Invitrogen) or
GAPDH as described.
Tumor and bone metastasis models

For intracardiac injections, the operator was

blinded to genotype. Mice were anesthetized and injected via the left ventricular chamber
with 1x105 B16-FL cells in 50 µL PBS(Hirbe et al., 2007). Bioluminescence imaging was
performed on days 7, 10, and 12 after B16-FL cell injection. For in-vivo imaging, mice
were injected i.p. with 150 mg/kg D-luciferin (Biosynthesis) in PBS 10 min before
imaging. Imaging was performed using a charge-coupled device camera (IVIS 100;
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exposure time of 1 or 5 min, binning of 8, field of view of 15 cm, f/stop of 1, and no
filter) in collaboration with the Molecular Imaging Center Reporter Core at Washington
University. Mice were anesthetized by isoflurane (2% vaporized in O2), and shaved to
minimize attenuation of light by pigmented hair. For analysis, total photon flux (photons
per second) was measured from a fixed region of interest in the tibia/femur or the
mandible using Living Image 2.50 and IgorPro software (Wavemetrics).
Flow Cytometry Spleen cells were prepared by gently crushing the tissue and filtering
through a 40-µm cell strainer (BD Falcon). Cells were harvested, centrifuged, and
incubated in red blood cell (RBC) lysis buffer. In stimulation experiments, cells were
incubated in 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h at 37°C.
Brefeldin A (Sigma-Aldrich) was added during the last 2 h of culture at 10 µg/ml. Cells
were stained with LIVE/DEAD Fixable Dead Cell Stain Kits (Molecular Probes,
Invitrogen) followed by the appropriate surface antibody (anti-CD4) for 20 min at 4°C.
Stained cells were fixed in 2% paraformaldehyde for 20 min at RT before
permeabilization with 0.05% saponin. Intracellular staining for the cells was conducted at
4°C for 30 min using Alexa Fluor 488 anti-mouse IL-17A (1:1000 dilution)
(eBioscience). Samples were gated on live cells using the above LIVE/DEAD cell stain.
All samples were analyzed on a FACSCalibur or FACSCanto (BD) and data were
analyzed with FlowJo software (TreeStar). A total of 30,000 events were collected per
sample.
Signaling experiments For BMM signaling, macrophages were grown in α-10 medium
and 1/10 CMG14-12 supernatant for 3 days. Cells were then starved of serum and M-
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CSF for 24 hours before being stimulated with either RANKL, M-CSF, IL-17, or TNFα.
For pre-osteoclast signaling, BMMs were grown for 48 hours in CMG and RANKL
before 4 hours of serum starvation, followed by cytokine stimulation for the appropriate
time periods. Total cell lysates were collected and Western blot analysis was performed.
Immunoprecipitation Cells were washed in cold PBS and lysed on ice in buffer (20
mM Tris, pH 7.4, 150 mM NaCl, 0.2% NP-40, 1 mM EDTA, and protease inhibitors).
Lysates were passed through a 25-gauge needle 10 times, incubated on ice for 30
minutes, and then clarified by centrifugation at 13,000 g for 15 minutes. One milligram
of protein was incubated with 5–10 µg of antibodies overnight with rotation. Protein A/G
agarose was then added and incubated with rotation for 3 hours at 4°C.
Immunoprecipitates were washed 4 times in lysis buffer, and solubilized proteins were
separated by SDS-polyacrylamide gels.
Proliferation and cell death ELISA assay BrdU proliferation assay was performed by
incubating cells for 18 hours in BrdU, followed by ELISA detection using the cell
proliferation Biotrak ELISA system (Amersham). Cell death was analyzed in
quadruplicate using cell death detection ELISAPLUS kit (Roche), which detects
cytoplasmic histone-associated DNA fragmentation.
Retroviral DNA constructs

All constructs were cloned into the pMXs-IRES-Puro

retroviral vector (Cell Biolabs, Inc., San Diego, CA). Vector only retrovirus were used as
controls.
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Retroviral transduction Retroviral transduction of bone marrow macrophages was
done as previously described(Zhao et al., 2008). 10 ug of retroviral DNA was transfected
into Plat-E cells using the Fugene HD transfection reagent (Roche, Basel, Switzerland)
the same day as bone marrow isolation. Plat-E media was replaced 24 hours later and
virus harvested 48 and 72 hours after for transduction of plated bone marrow cells. To
transduce the bone marrow cells, culture media was replaced at 48 and 72 hours with
alpha10 containing 50% Plat-E viral media, 10% CMG 14-12 supernatant, and 4ug/mL
polybrene. At 96 hours the transduction media was replaced with alpha10 with 10%
CMG 14-12 supernatant and 2 ug/mL puromycin. Cells were selected for 3 days before
being harvested and plated to form osteoclasts, at which time non-transduced control
cells were killed by the puromycin.
Osteoclastogenesis Osteoclasts were grown on plastic in 48-well plates for 3-5 days and
fixed with 4% PFA, as described above. TRAP staining on fixed cells was performed
using a commercially available kit according to the manufacturer's instructions (Sigma,
St. Louis, MO). All TRAP+ cells with at least three nuclei were counted, with 2-3 wells
counted per genotype.
Calvaria osteoblast isolation and culture Whole calvaria were extracted from 3-4 day
old pups and cleaned of soft and periostial tissue. Osteoblasts were liberated by 3x 20
minute collagenase treatment at 37 degrees, shaking. Osteoblasts were transduced with
appropriate virally expressed proteins when 50% confluent, selected with the appropriate
antibiotic for 4 days, then plated for experiments. For cocultures, BMMs were cultured
for 4 days prior to being lifted and then cultured with osteoblasts in α-MEM media
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containing pen/strep, 10% FBS and 10nM VitD3, plus IL-17 or other cytokines where
indicated.
Immunoblots Cells were lysed in RIPA buffer + protease inhibitors for 10 minutes on
ice, the lysates were clarified, 5x Laemmli sample buffer added, and the samples boiled.
Immunoblotting was performed using antibodies against β-actin (Sigma-Aldrich, St.
Louis MO) (1:40,000 dilution), c-Src (monoclonal antibody directed against c-Src was a
gift from A. Shaw) (final concentration: 2ug/mL), β3 integrin, JNK, p-JNK, p38, p-p38,
Akt, p-Akt, ERK, p-ERK, IκB, p-IκB (Cell Signaling Technology); monoclonal anti-HA
(Covance); cathepsin K (Millipore, Billerica, MA) (1:500 dilution), and Alexa Fluor 488–
conjugated phalloidin (Invitrogen). Quantification of immunoblot results was performed
using a Storm 840 phosphorimager (Molecular Dynamics, Piscataway, NJ) and
ImageQuant software (GE, Piscataway, NJ).
Microcomputed tomography and ovariectomy

Trabecular volume in the distal

femoral metaphysis (right leg) was measured using in vivo microcomputed tomography
(vivaCT 40, Scanco Medical, Brüttisellen, Switzerland) while the mice were anesthetized
with isofluorane. A threshold linear attenuation coefficient of 1.2 cm−1 was used to
differentiate bone from non-bone. A threshold of 220 was used for evaluation of all
scans. 30 slices were analyzed, starting with the first slice in which condyles and primary
spongiosa were no longer visible.

Measurements were made 28 days after sham

operation or ovariectomy (ovx), unless otherwise indicated. Measurements included
bone volume/total volume (BV/TV), connectivity density (Conn. Dens), structure model
index (SMI), trabecular separation (Tb.Sp), trabecular thickness (Tb.Th), and trabecular
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number (Tb.N). For ovariectomies, all mice were aged 8 weeks at time of ovx. Mice
were anesthetized with ketamine/xylene delivered by intraperitoneal injection, and
ovaries were removed through two small dorsal incisions. Sham operated mice were
anesthetized and opened equivalently, but ovaries were not removed.
Electron microscopy Proximal tibiae of 2-month-old mice were fixed with 4% PFA
overnight and decalcified in 14% EDTA for 7 days. The samples were then postfixed in
2% OsO4/3% K-ferrocyanide for 2 hr, dehydrated in ethanol, and embedded in Epon LX
112. Ultrathin sections were stained briefly with lead citrate and examined using a JEOL
100SX transmission electron microscope.
Serum Ctx measurements

Blood was collected by cheek puncture after 6 hours

starvation. Plasma was obtained using plasma separator tubes with lithium heparin
(Becton Dickinson). Serum CTx-I, a specific marker of osteoclastic bone resorption, was
measured using a RatLaps ELISA kit from Nordic Bioscience Diagnostics A/S.
Statistics All data was analyzed with Prism software (Graphpad, San Diego, CA), using
two-tailed unpaired Student’s t tests, unless otherwise indicated. Error bars represent
standard deviation.
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Chapter 4: Halofuginone Prevents
Osteoporosis in Mice
Abstract
Osteoporosis is characterized by low bone mass, leading to fracture in an
estimated one of two women, and one of five men over 50 (Cooper, ; Gass & DawsonHughes, 2006). Bone loss develops when activity of the bone-resorbing osteoclast
outweighs that of the bone-forming osteoblast. Although the osteoblast creates new
bone, it also produces RANKL, the most potent osteoclast activator. RANKL production
is stimulated by IL-17, leading to bone loss in inflammatory arthritis (Miossec, 2003),
and contributing to bone loss in estrogen deficiency (other paper). IL-17 is primarily
produced by Th17 T cells, which can be effectively inhibited by the small molecule
Halofuginone (Sundrud et al., 2009). We find Halofuginone treatment protects mice
from estrogen-deficiency bone loss, a model of the most prevalent form of osteoporosis
in humans. Halofuginone does not directly inhibit osteoclast formation, but rather
reduces the number of IL-17 producing T cells. Less osteoblastic IL-17 stimulation
results in less RANKL production, and lower serum markers of bone resorption. Thus,
Halofuginone is a novel potential therapeutic for bone loss in the estrogen-deficient state.
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Introduction
For centuries the roots of Dichroa febrifuga have been used in ancient Chinese
herbal medicine to treat malarial fevers. The active ingredients were identified as
febrifugine and its stereoisomere, isofebrifugine. Halofuginone (7-bromo-6-chloro-3-[3(3-hydroxy- 2-piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone) is a febrifugine analogoue
used in commercial poultry production for coccidiosis infection. Its utility in treating
fibrotic conditions, such as scleroderma, in humans has since been established. In 2009,
it was reported in Science to also inhibit production of IL-17 (Sundrud et al., 2009).
The anti-sclerosis properties of Halofuginone are thought to arise from its ability to
inhibit production of type I collagen by fibroblasts, which is the main constituent of
fibrous tissue. Halofuginone inhibits collagen α1(I) mRNA and protein levels in a
variety of cells, including mouse skin fibroblasts, avian growth plate chondrocytes, a
transformed rat embryo cell line, vascular smooth muscle cells, bovine aortic endothelial
cells, and rat liver stellate cells (Bruck et al., 2001; Choi, Callow, Sehgal, Brown, &
Ryan, 1995; Granot, Halevy, Hurwitz, & Pines, 1993). Collagen type II or III were not
inhibited in these studies (Choi et al., 1995; Granot et al., 1993). Halofuginone is shown
to inhibit fibrosis accumulation in rat urethral stricture formation (Nagler et al., 2000),
thioacetamide- and dimethylnitrosamine-induced rat cirrhosis (Bruck et al., 2001; Pines,
Knopov, Genina, Lavelin, & Nagler, 1997), rat pulmonary fibrosis after bleomycin
treatment (Nagler et al., 1996), and tight skin (Tsk)+ and cGvHD-afflicted mice (LeviSchaffer, Nagler, Slavin, Knopov, & Pines, 1996; McGaha, Phelps, Spiera, & Bona,
2002; Pines et al., 2001). The drug was effective whether given orally, locally, or
intraperitoneally. The mechanism by which Halofuginone decreases collagen type I is
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unclear, but seems to require new protein synthesis, since cycloheximide or actinomycin
D blocks the suppressive effect of halofuginone on collagen α1(I) mRNA expression
(Halevy, Nagler, Levi-Schaffer, Genina, & Pines, 1996). Its antifibrotic effects may be
due to inhibition of TGFβ1 signaling (McGaha et al., 2002), but at concentrations that
inhibit IL-17 production, no TGFβ inhibition is seen (Sundrud et al., 2009). Rather,
Halofuginone induces the amino acid starvation response, which through unknown
mechanisms prevents IL-17 production and Th17 development, a process that cannot be
rescued by forced RORγt expression (Sundrud et al., 2009). In most animal models of
fibrosis, regardless of the tissue, halofuginone had a minimal effect on collagen content
in the control, nonfibrotic animals, whereas it exhibited a profound inhibitory effect in
the fibrotic organs. In culture, halofuginone was effective in reducing collagen synthesis
by fibroblasts after they had been stimulated with a profibrotic agents, but had a very
small effect on collagen synthesis in control cells (McGaha et al., 2002). Even in animal
models of pre-existing fibrosis, Halofuginone treatment can reduce fibrotic levels to
normal levels (Nagler et al., 1998).
Given the promise of Halofuginone in treatment of systemic sclerotic conditions,
Phase I-III studies have been performed using the drug topically, as well as a Phase I
study for oral administration. The oral study was double-blind and involved 26 healthy,
male volunteers receiving between 0.07 to 2.5 mg/d with food. Single, oral doses of 0.07
and 0.5 mg Halofuginone were found to be safe and well tolerated, with no clinically
significant adverse events. At 1.5 to 2.5 mg, Halofuginone was moderately tolerated,
with incidence of nausea and vomiting associated with dose escalation. A daily dose of
1.5 mg Halofuginone was designated as the maximal tolerated dose. A later study found
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that dividing the dose into several daily portions allowed greater intake without
increasing gastrointestinal adverse events (Pines, Snyder, Yarkoni, & Nagler, 2003).
Since earlier studies in this thesis implicate IL-17 in the pathogenesis of
osteoporosis, we tested whether Halofuginone administration post-ovariectomy has an
effect on IL-17 production and bone mass, and find Halofuginone to be a novel potential
therapeutic for treatment of osteoporosis.
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Results
Halofuginone Protects from Osteoporosis
To mirror the most common form of osteoporosis in humans, we produced an
estrogen-deprived state by ovariectomizing (ovx) mice. Beginning the day of ovx, mice
were treated with vehicle or Halofuginone at a dose reported to inhibit IL-17 production
(Sundrud et al., 2009). After two weeks, bone volume (BV) was significantly reduced in
vehicle treated ovx mice relative to sham, but not in ovx mice treated with Halofuginone
(Figure 4.1). Bone volume per total volume (BV/TV) was significantly lower in vehicle
treated ovx mice compared with either sham or Halofuginone treated ovx mice. Flow
cytometry analysis of spleen cells showed the percentage of CD4+ T-cells producing IL17 was significantly reduced in Halofuginone treated mice after two weeks (Figure 4.2).
Carboxy-terminal collagen crosslinks (CTx) are released from the bone upon resorption,
and serum levels are used to measure levels of systemic bone resorption (Rosen et al.,
2000). Two weeks after ovx, vehicle treated mice have significantly higher levels of
serum CTx, while Halofuginone treated mice have a blunted, non-statistically significant,
increase in the serum marker of bone resorption (Figure 4.3). By four weeks, BV/TV,
BV, connectivity density, trabecular thickness, and trabecular number were all
significantly reduced in ovx mice compared with sham, but not in Halofuginone treated
ovx mice relative to sham (Figure 4.4). These data indicate Halofuginone treatment after
ovx protects mice from bone loss associated with the estrogen-deprived state.
Halofuginone does not directly affect osteoclast formation or bone formation
To exclude the possibility that Halofuginone directly inhibits osteoclasts, we
culutured bone marrow macrophages in RANKL and M-CSF plus varying concentrations
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of Halofuginone. While 10 ug/ml was toxic to macrophages in the culture, other
concentrations had no effect on osteoclast formation (Figure 4.5).
Since Halofuginone inhibits type I collagen synthesis by fibroblasts and other cells,
we tested whether bone formation rates are reduced in mice treated with the chemical.
Calcein double labeling of mice treated for two weeks with Halofuginone or PBS control
showed equivalent bone formation rates (Figure 4.6), indicating Halofuginone does not
affect bone formation.

Halofuginone treated mice have less body fat
IL-17A inhibits adipocyte differentiation from human mesenchymal stem cells
(Shin, Shin, & Noh, 2009). IL17R-/- mice are heavier and have higher leptin levels,
which is a marker of adopocyte mass (Galic, Oakhill, & Steinberg, ; Goswami,
Hernandez-Santos, Zuniga, & Gaffen, 2009). Leptin can stimulate IL-17 production (Liu
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et al., 2008), and blood IL-17 levels are increased in obese women (Sumarac-Dumanovic
et al., 2009). These data implicate the Th17 axis in adiposity, so we used magnetic
resonance imaging (MRI) as a sensitive measure of body composition after 12 weeks of
treatment with Halofuginone or vehicle control. We expected inhibition of IL-17 may
lead to increased adiposity, but instead Halofuginone treated mice had significantly less
total fat mass, in addition to reduced percent body fat (Figure 4.7). Additionally,
Halofuginone treatment resulted in a small but statistically significant increase in percent
lean mass (Figure 4.7).

140

141

142

Discussion
Halofuginone is reported to inhibit IL-17 production in vivo, and since IL-17 is
implicated in bone destruction in arthritis (Lubberts) and osteoporosis (previous chapter),
we tested the effect of Halofuginone on bone loss in the mouse model of osteoporosis.
We find treatment with Halofuginone prevents the majority of the bone loss induced by
ovariectomy. Since Halofuginone inhibits collagen type I synthesis, we expected bone
formation rates might be reduced in Halofuginone treated animals. However, no
differences were observed in bone formation. One explanation for this is that
Halofuginone inhibits collagen synthesis more in conditions where fibrosis is
extravagant, and not at baseline (McGaha et al., 2002). Another explanation is that at the
concentrations used in these experiments, IL-17 production is affected, but TGFβ
signaling is not (Sundrud et al., 2009), and it is the effects on TGFβ that are thought to
interfere with collagen synthesis (McGaha et al., 2002). Since IL17R-/- mice are
protected from osteoporosis, Halofuginone likely works on bone by reducing IL-17
production, leading to less IL-17 signaling in osteoblasts, less RANKL production, and
less osteoclastic bone resorption (as shown in the previous chapter). Additionally, Th17
cells express high levels of RANKL and may directly mediate bone destruction (Sato et
al., 2006), suggesting that reduction of CD4+ IL-17+ T-cells using Halofuginone may
have beneficial effects on the bone independent of the osteoblast.
It is interesting to note that BATF KO mice, which are reported to lack Th17 cells
(Schraml et al., 2009), are not protected from ovx-induced bone loss, in contrast to mice
treated with Halofuginone or IL-17 blocking antibody (previous chapter). This suggests
Halofuginone does more than inhibit Th17 cell development, and may inhibit production
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of IL-17 by other cell types as well. If it is not Th17 cells, it will be interesting to
determine the IL-17 producing cell type responsible for bone loss induced by estrogen
deficiency.
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Methods
Mice All animals were housed in the animal care unit of the Washington University
School of Medicine and were maintained according to guidelines of the Association for
Assessment and Accreditation of Laboratory Animal Care. All animal experimentation
was approved by the Animal Studies Committee of the Washington University School of
Medicine.
Reagents

Halofuginone was purchased from Mingdou Chemical Company Ltd.

(Shanghai, China).
Histological analysis Tibias were harvested, cleaned of soft tissue, and fixed in 10%
buffered formalin overnight. For non-decalcified sections, tibias were dehydrated by
incubation in an ethanol gradient (20%, 30%, 50%, 70% ETOH, for 30 minutes each).
Bones stored in 70% ETOH were then embedded in methylmethacrylate and cut into 5µm
longitudinal sections. Non-decalcified sections were left unstained. For decalcified
sections, following fixation, tibias were rinsed in water then incubated in 14% EDTA (pH
7.2) for 7 days with solution changes every 3.5 days. Following decalcification, tibias
were rinsed in water then incubated in the ETOH gradient described above. Bones stored
in 70% ETOH were then embedded in paraffin, cut into 4µm longitudinal sections, and
stained with TRAP or hematoxylin and eosin for visualization of osteoclasts or
osteoblasts, and measurements were made using BioQuant software (Bioquant;
Nashville, TN).
Bone formation assay (calcein double labeling) Mice were injected with 7.5mg/kg
calcein (Sigma-Aldrich; St. Louis, MO). Five days later mice were injected again, and
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tibias were harvested after an additional 2 days for histologic analysis.

Dynamic

assessment of trabecular bone formation was determined on non-decalcified sections
using BioQuant software (Bioquant; Nashville, TN). This software provided measures of
bone surface, percent single- (sLS/BS) and double-labeled (dLS/BS) bone surface,
mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate
(BFR/BS). Trabecular bone measurements were taken from a region encompassing a
500µm-long field, across the width of the bone (located 100µm below the growth plate).
For each animal, 2 serial sections were analyzed and the measurements averaged.
Pictures were obtained using an Olympus 1X51 fluorescent microscope fitted with
Olympus DP70 camera (Olympus; Center Valley, PA).
Cell culture Osteoclasts were grown in alpha10 media, containing alpha-MEM (Sigma
Aldrich, St. Louis, MO), 10% fetal calf serum (Hyclone, Waltham, MA), 100U/mL
penicillin and 100ug/mL streptomycin. Plat-E retrovirus packaging cells were purchased
from Cell Biolabs, Inc. (San Diego, CA) and maintained in DMEM media (Cellgro,
Manassas, VA) containing 10% fetal calf serum (Hyclone, Waltham, MA), and 2mM Lglutamine (Gibco, Carlsbad, CA). Osteoclasts were differentiated from bone marrow as
described(Zhao et al., 2008). Briefly, bone marrow was extracted from mice and cultured
in the presence of 10% CMG 14-12 supernatant(Takeshita, Kaji, & Kudo, 2000), a MCSF-containing cell supernatant. After 4 days, cells were lifted and replated on plastic or
bovine bone fragments in alpha10 media supplemented with 2% CMG and 100ng/mL
recombinant RANKL. Bone-grown cells were fixed in 4% paraformaldehyde 6 or 7 days
after plating.

Plastic-grown cells were fixed on days 3, 4, and 5 in 4%
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paraformaldehyde/PBS for osteoclastogenesis analysis or lysed on various days for
immunoblot analysis.
RT-PCR

RNA was isolated using RNeasy kits (Qiagen); RLT lysis buffer was

supplemented with β-mercaptoethanol (1%). Purified RNA was treated with DNase I
(Invitrogen; Carlsbad, CA) prior to reverse transcription (RT). RT was performed using
SuperScript III (Invitrogen). A negative control using RNA not subjected to reverse
transcription was included in each assay. Quantitative PCR (qPCR) was performed using
Applied Biosystems’s (Foster City, CA) Power SYBR green master mix and gene
specific primers. The qPCR reaction was run on Applied Biosystem’s ABI Prism 7000.
Transcript levels were normalized to cyclophilin.
Flow Cytometry Spleen cells were prepared by gently crushing the tissue and filtering
through a 40-µm cell strainer (BD Falcon). Cells were harvested, centrifuged, and
incubated in red blood cell (RBC) lysis buffer. In stimulation experiments, cells were
incubated in 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h at 37°C.
Brefeldin A (Sigma-Aldrich) was added during the last 2 h of culture at 10 µg/ml. Cells
were stained with LIVE/DEAD Fixable Dead Cell Stain Kits (Molecular Probes,
Invitrogen) followed by the appropriate surface antibody (anti-CD4) for 20 min at 4°C.
Stained cells were fixed in 2% paraformaldehyde for 20 min at RT before
permeabilization with 0.05% saponin. Intracellular staining for the cells was conducted at
4°C for 30 min using Alexa Fluor 488 anti-mouse IL-17A (1:1000 dilution)
(eBioscience). To determine background levels of cytokine staining, a set of cells was
not stimulated, but was treated with brefeldin A and stained for intracellular cytokines, as
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was done for experimental cells. Samples were gated on live cells using the above
LIVE/DEAD cell stain. All samples were analyzed on a FACSCalibur or FACSCanto
(BD) and data were analyzed with FlowJo software (TreeStar). A total of 30,000 events
were collected per sample.
Osteoclastogenesis Osteoclasts were grown on plastic in 48-well plates for 3-5 days and
fixed with 4% PFA, as described above. TRAP staining on fixed cells was performed
using a commercially available kit according to the manufacturer's instructions (Sigma,
St. Louis, MO). All TRAP+ cells with at least three nuclei were counted, with 2-3 wells
counted per genotype.
Calvaria osteoblast isolation and culture Whole calvaria were extracted from 3-4 day
old pups and cleaned of soft and periostial tissue. Osteoblasts were liberated by 3x 20
minute collagenase treatment at 37 degrees, shaking. Osteoblasts were transduced with
appropriate virally expressed proteins when 50% confluent, selected with the appropriate
antibiotic for 4 days, then plated for experiments. For cocultures, BMMs were cultured
for 4 days prior to being lifted and then cultured with osteoblasts in α-MEM media
containing pen/strep, 10% FBS and 10nM VitD3, plus IL-17 or other cytokines where
indicated.
Microcomputed tomography and ovariectomy

Trabecular volume in the distal

femoral metaphysis (right leg) was measured using in vivo microcomputed tomography
(vivaCT 40, Scanco Medical, Brüttisellen, Switzerland) while the mice were anesthetized
with isofluorane. A threshold linear attenuation coefficient of 1.2 cm−1 was used to
differentiate bone from non-bone. A threshold of 220 was used for evaluation of all
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scans. 30 slices were analyzed, starting with the first slice in which condyles and primary
spongiosa were no longer visible.

Measurements were made 28 days after sham

operation or ovariectomy (ovx), unless otherwise indicated. Measurements included
bone volume/total volume (BV/TV), connectivity density (Conn. Dens), structure model
index (SMI), trabecular separation (Tb.Sp), trabecular thickness (Tb.Th), and trabecular
number (Tb.N). For ovariectomies, all mice were aged 8 weeks at time of ovx. Mice
were anesthetized with ketamine/xylene delivered by intraperitoneal injection, and
ovaries were removed through two small dorsal incisions. Sham operated mice were
anesthetized and opened equivalently, but ovaries were not removed.
MRI Measurements of body composition were performed using the magnetic resonance
imaging facility located at the Animal Model Research Core at Washington University
(CNRU grant NIH P30 DK56341).
Serum Ctx measurements

Blood was collected by cheek puncture after 6 hours

starvation. Plasma was obtained using plasma separator tubes with lithium heparin
(Becton Dickinson). Serum CTx-I, a specific marker of osteoclastic bone resorption, was
measured using a RatLaps ELISA kit from Nordic Bioscience Diagnostics A/S.
Statistics All data was analyzed with Prism software (Graphpad, San Diego, CA), using
two-tailed unpaired Student’s t tests, unless otherwise indicated. Error bars represent
standard deviation.
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Chapter 5: Conclusion
The first chapter in this thesis establishes autophagy proteins as novel regulators
of lysosome secretion in osteoclasts. We show that the autophagy protein LC3 localizes
to the ruffled border in wild type bone grown osteoclasts, but not those lacking the
autophagy protein ATG5. ATG5 deficient osteoclasts form more shallow bone pits, and
also are defective in localizing Cathepsin K and Lamp1 to the ruffled border, suggesting
a defect in secretion. Osteoclasts lacking Atg7 display a similar phenotype. Dominant
negative Atg4b also prevents LC3 localization to the ruffled border, resulting in
mislocalized Cathepsin K and Lamp1, and impaired bone resorption. The lysine on
position 130 of Atg5 is critical for its function of both LC3 and CatK localization, as wild
type Atg5 but not K130R-Atg5 successfully restores the osteoclast phenotype.
Consistent with a role in secretion, ruffled border formation is attenuated in
osteoclasts lacking Atg5. Although the precise role of LC3 at the ruffled border is
unclear, it is likely not localized here by autophagosomes, as immunoEM against GFPLC3 reveals the protein is concentrated near the bone-apposed plasma membrane, not on
autophagosomes, and is directly associated with ruffled border plasma membrane in
actively resorbing osteoclasts. These data may help explain GWAS data implicating the
autophagy cascade in risk for osteoporosis and height variability.
Again focusing on mechanisms of bone loss, Chapter 3 implicates a novel
pathway in the pathogenesis of osteoporosis. Although osteoporosis is not traditionally
thought of as an inflammatory disease, a critical role for T cells has been established by
Dr. Pacifici’s group. The specific type of T cell involved has not been investigated, but
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Th17 cells are an obvious candidates given their strong effects on bone resorption during
arthritis, in contrast to the anti-osteoclastic effects of the Th1 cytokine IFNγ. Indeed, we
find IL17R-/- mice are protected from ovariectomy-induced bone loss. Furthermore, IL17 neutralizing antibody injected post ovariectomy protects them from bone loss, as does
a drug recently reported to inhibit IL-17 production (Halofuginone).
IL-17 does not directly stimulate osteoclasts or their precursors, but rather acts on
the osteoblast to increase RANKL production. Neutralizing IL-17 antibody abolishes the
osteoclastogenic effect of IL-17 in coculture. Structure/function analysis of the IL-17
receptor indicates the SEFIR domain is critical for RANKL upregulation. This domain
likely functions by interacting with the scaffolding protein Act1, and Act1-/- mice are
also protected from bone loss due to ovariectomy. Although Act1 is a ubiquitin ligase for
TRAF6, we find Act1 does not have a direct role in osteoclast formation, but rather is
critical in the osteoblast for IL-17 induced RANKL expression.
These experiments provide evidence for a non-canonical role of the autophagy
cascade in lysosome secretion. Additionally, this thesis identifies autophagy proteins and
the IL-17 pathway as critical regulators of osteoclast function and bone resorption.
Finally, a novel therapeutic for osteoporosis is described, which we have submitted for
patent.

153

Chapter 6: Future Directions
Autophagy in the Osteoblast
Background
The autophagy pathway is linked to bone density and height variation in human
GWAS analysis (Pan et al., ; Zhang et al.), and this thesis demonstrates the importance of
autophagy on osteoclast secretion. However, autophagy is most critical in long-lived
cells, such as neurons, which must not only survive varying nutritional states but must
also dispose of unwanted proteins and damaged organelles efficiently, as cell death and
regeneration is not an option. Osteoclasts are relatively short lived cells, which may be
why autophagy is not used for osteoclast survival. Osteoblasts, however, survive for long
periods, then become osteocytes which live for decades in the bone. Therefore,
autophagy’s role in survival of osteoblasts and osteocytes may be critical. Furthermore,
osteoblasts have a similar secretory apparatus as osteoclasts (Zhao et al., 2008). They
synthesize and secrete type I collagen, non-collagen proteins, and growth factors, creating
the bone matrix (osteoid) (Harada & Rodan, 2003). Another round of secretion occurs as
osteoblasts secrete matrix vesicles, which are membrane-bound extracellular structures
that mediate mineralization of the osteoid (Anderson, 1995). Therefore, we hypothesize
autophagy is important for osteoblast survival or function.
Experimental Design
We will breed the collagen I-cre (ColI-cre) mouse (from Fanxin Long), which
expresses cre recombinase in osteoblasts, to Atg5-flox/flox and Atg7-flox/flox mice
(from Skip Virgin). The bone phenotype will be assessed by in vivo uCT at ages of 8
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weeks, and older if a phenotype is observed. Tetracycline double label will be performed
to assess bone formation rates in vivo. Osteoid and osteoblast number will be determined
histologically. Cre+ and cre- osteoblasts will be isolated from calvariae, cultured, and
assayed for proliferation rate (BrdU incorporation), bone nodule formation, apoptosis,
and differentiation. Differentiation will be assessed by staining cells for alkaline
phosphotase (ALP), and by analyzing RNA levels of ALP and osteocalcin at various days
of differentiation (0, 3, 7, 14, 21). Bone nodules will be assessed by alizarin red staining.
Results of these experiments will dictate further direction, such as pursuing the effect of
autophagy on the osteocyte.
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TI-Vamp and Secretion in the Osteoclast
Background
Osteoclasts secrete lysosomes and endosome-derived organelles to resorb bone.
Thus far, all that is known of vesicle exocytosis in osteoclasts is that Synaptotagmin-VII
is necessary (Zhao et al., 2008), acting as a SNARE-regulating calcium sensor. The direct
involvement of specific SNARE proteins has not been shown. TI-VAMP (VAMP7) is a
v-SNARE involved in lysosome-late endosome fusion (Pryor et al., 2004), lysosomeplasma membrane fusion (Logan et al., 2006; Mollinedo et al., 2006), lysosomeautophagosome fusion (Fader, Sanchez, Mestre, & Colombo, 2009), and granule
exocytosis (Logan et al., 2006; Mollinedo et al., 2006) in various cell types, and is thus a
prime candidate for mediating lysosome exocytosis in the osteoclast.
Experimental Design
No TI-Vamp knockout or floxed mice currently exist. Thus, siRNA knockdown
or overexpression of the protein are the best available techniques. If siRNA data
demonstrates a strong phenotype, it may be grounds to create a knockout and/or floxed
TI-VAMP mouse. Important siRNA-based assays will be CTx of media surrounding
bone grown osteoclasts, bone pit formation (morphology and depth), visualization of
CatK by confocal microscopy to observe for mislocalization and accumulation, and
perhaps electron microscopy of bone grown osteoclasts to assess ruffled border
formation. Significant defects in these assays with least two different siRNA constructs
should be demonstrated before a knockout of floxed mouse is made.
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Plekhm1 in Autophagy and Bone Resorption
Background
In the search for novel regulators of autophagy and bone resorption, Plekhm1
(pleckstrin homology domain containing, family member 1) is an important candidate.
Plekhm1 is a homologue of Rubicon, a newly discovered negative regulator of
autophagy. Rubicon localizes to the endosome/lysosome, and binds Vps34 and UVRAG
(Zhong et al., 2009). Knockdown of Rubicon promotes of autophagy (Matsunaga et al.,
2009), while forced expression of Rubicon caused aberrant late endosomal/lysosomal
structures and impaired autophagosome maturation (Zhong et al., 2009).
Plekhm1 was identified as a spontaneous mouse mutation that caused osteopetrosis.
Mutant osteoclasts lack ruffled borders and lack extracellular TRAP, but accumulate the
protein intrcellularly, suggesting a defect in secretion (Reinholt et al., 1999). Like
Rubicon, Plekhm1 localizes to lysosomes and late endosomes (Van Wesenbeeck et al.,
2007). Plekhm1 mutation is associated with osteopetrosis in humans (Van Wesenbeeck
et al., 2007).
Although thus far unpublished, Rubicon and Plekhm1 are fairly homologous. A
BLAST search for Plekhm1 returns Rubicon, and a Clustal W multiple sequence
alignment reveals similarity between the two proteins (Figure 6.1). While Plekhm1 is
highly expressed in mouse osteoclasts (Figure 6.2), Rubicon is not (Figure 6.3). It is
possible Plekhm1 and Rubicon have similar functions, with Plekhm1 being dominantly
expressed in osteoclasts, and Rubicon in other cell types.
If Plekhm1 and Rubicon have similar functions, one would expect Plekhm1 to
negatively regulate autophagosome maturation. It is already known Plekhm1 positively
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Key:
Red letters = small and hydrophobic, Blue = acidic, Magenta = basic, Green =
basic with a hydroxyl and amine. Below the alignment:
"*" means the residues or nucleotides in that column are identical in all
sequences in the alignment.
":" means conserved substitutions have been observed.
"." means semi-conserved substitutions are observed.
Figure 6.1: Sequence alignment of Plekhm1 and Rubicon
Human Plekhm1 (sequence obtained from Pubmed: NM_014798.2) and Human
Rubicon (sequence obtained from Pubmed: KIAA0226) mRNA sequences were
aligned using Clustal W2 alignment tool (available at
http://www.ebi.ac.uk/Tools/clustalw2/index.html).
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Figure 6.2: Plekhm1 mRNA is expressed at high levels in macrophage lineage cells,
including osteoclasts
The first vertical line represents the median gene expression level across all tissues.
Bone cells are represented in light green. Osteoclasts express high levels of Plekhm1
compared to osteoblasts and other non-macrophage cells.
Source: biogps.gnf.org
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Figure 6.3: Rubicon mRNA is expressed at high levels in macrophage lineage cells,
including osteoclasts
Bone cells are represented in light green. Osteoclasts express low levels of Rubicon.
Source: biogps.gnf.org/, search term: KIAA0226
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regulates secretion in the osteoclast. Thus, my hypothesis is that 1) Plekhm1 negatively
regulates traditional autophagy, and 2) Plekhm1 acts as the molecular switch that
channels autophagy related proteins to perform secretory duties rather than
autophagosome formation.
Experimental Design
The first task will be to determine whether Plekhm1 regulates traditional
autophagy. Based on personal observation, autophagosomes are relatively lacking in
osteoclasts, so one approach would be to knockdown Plekhm1 in the osteoclast using
retroviral expression of shRNA and monitor autophagosome formation. LC3-positive
puncta could be measured by immunofluorescence, but the best method would be to
identify and count autophagosomes by electron microscopy (the cells could be grown on
plastic rather than bone, making the process easier). Other cell types could also be used,
and in cells that have higher basal autophagosome formation, overexpression of Plekhm1
may inhibit autophagosome formation. LC3 conjugation should not be used in these
studies, because if Plekhm1 diverts autophagy machinery for secretory function, LC3
conjugation will likely be intact.
In Plekhm1 knockdown cells, it would be interesting to see if less LC3 localizes to
the ruffled border of bone grown osteoclasts, and vice versa in Plekhm1 overexpression.
One would have to infect GFP-LC3 transgenic osteoclasts with the shRNA or expression
vector, then stain for GFP and actin, as described in Chapter 2.
Since Plekhm1 has been knocked out by the International Knockout Mouse
Consortium, it would be interesting to characterize the phenotype, specifically looking at
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autophagy. One would expect higher autophagy flux in cells of this mouse, although cell
to cell variability may be observed. Based on expression data, the best cells to
characterize may be macrophages and osteoclasts. An osteoclast phenotype is already
known, but given that Plekhm1 is even more highly expressed in macrophages, and the
autophagy pathway seems to be important for many functions in these cells, it would be
particularly interesting to study macrophages in these knockout mice.
If Plekhm1 is identified as a regulator of autophagy, it would be the first molecular
switch to date that determines whether autophagy machinery are used for autophagosome
formation or for other uses. Thus, it would be necessary to determine how the protein
itself is regulated, and perform a structure/function analysis.
Conclusion
Although this thesis describes autophagy proteins as regulators of osteoclast
function, they may have additional roles in the osteoblast. The autophagy cascade may
have a similar function in both cell types, as in the case of Synaptotagmin VII, or may
simply function in osteoblast survival. Given GWAS data implicating the autophagy
cascade in bone density, it would be informative to characterize these proteins in both of
the cell types that affect bone turnover (the osteoclast and the osteoblast).
TI-VAMP is a SNARE protein important for autophagosome-lysosome fusion, as
well as secretion of lysosomes in a variety of cell types. From the autophagy viewpoint,
it is the best candidate for regulating secretion of lysosomes via autophagy-cascade
proteins; from the general lysosome secretion viewpoint, it is the best candidate SNARE
protein for mediating lysosome-plasma membrane fusion in the osteoclast. Thus, pursuit
of the role of this protein in osteoclast function seems high-yield.
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Finally, Plekhm1, being homologous to a negative regulator of autophagosome
formation (Rubicon) and being critical for osteoclastic secretion, is positioned as a
potential novel regulator of autophagy, especially in cells like the osteoclast that lack
high levels of Rubicon. Plekhm1 may serve as a molecular switch, directing autophagy
machinery from traditional functions, including autophagosome formation, toward noncanonical roles, such as secretion.
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